prednisolone has been researched along with Sjogren's Syndrome in 209 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Sjogren's Syndrome: Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the long-term outcome of autoimmune pancreatitis (AIP) including morphological changes in the pancreas, pancreatic duct, biliary tract, pancreatic function, and changes in the clinical manifestations after oral prednisolone (PSL) therapy." | 7.73 | Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. ( Nishino, T; Oyama, H; Shimizu, K; Shiratori, K; Toki, F, 2006) |
| "Sirolimus is an effective and safe treatment option for refractory CTD-TP patients." | 7.01 | Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. ( Li, M; Wang, Q; Wu, C; Xu, D; Zeng, X, 2021) |
| "Initial dosage of prednisolone was 15." | 6.69 | Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. ( Matoba, K; Miyawaki, S; Nishiyama, S, 1999) |
| "Tacrolimus was discontinued." | 6.48 | Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature. ( Imai, H; Komatsu, N; Nakamura, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Wakabayashi, M, 2012) |
| "We report a case of interstitial cystitis (IC) associated with primary Sjögren's syndrome (SS) successfully controlled with combination therapy of tacrolimus and a corticosteroid." | 5.43 | Interstitial cystitis associated with primary Sjögren's syndrome successfully treated with a combination of tacrolimus and corticosteroid: A case report and literature review. ( Kaneko, H; Kano, T; Mimori, A; Takahashi, H; Takahashi, Y; Tomoe, H; Ueda, Y; Yamashita, H, 2016) |
| "NK lymphocytosis is rarely associated with autoimmune disease, but the combination of indomethacin and steroid therapy may have a favorable effect for such patients." | 5.34 | Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil. ( Fujii, T; Fujita, Y; Mimori, T; Takeda, N; Tanaka, M, 2007) |
| " A total of 91 patients with systemic autoimmune diseases who received initial glucocorticoid therapy with prednisolone (30-60 mg daily) were prospectively enrolled." | 3.88 | Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases. ( Kaneko, K; Kawai, S; Kawazoe, M; Kusunoki, N; Nanki, T; Shikano, K, 2018) |
| " Renal tubular acidosis (RTA) was treated with alkali replacement and moderate-severe tubulointerstitial nephritis (TIN) was treated with oral prednisolone." | 3.88 | Renal involvement in primary Sjogren's syndrome: a prospective cohort study. ( Emmanuel, D; Jain, A; Jain, VK; Negi, VS; Parameshwaran, S; Srinivas, BH, 2018) |
| " This condition led to ileus, which was effectively treated using prednisolone." | 3.83 | Multiple Mesenteric Panniculitis as a Complication of Sjögren's Syndrome Leading to Ileus. ( Abe, Y; Egashira, Y; Fujiwara, K; Higuchi, K; Iguchi, M; Inoue, T; Kakimoto, K; Kawakami, K; Kojima, Y; Nouda, S; Okada, T; Takeuchi, T; Toshina, K; Yorifuji, N, 2016) |
| "We investigated the long-term outcome of autoimmune pancreatitis (AIP) including morphological changes in the pancreas, pancreatic duct, biliary tract, pancreatic function, and changes in the clinical manifestations after oral prednisolone (PSL) therapy." | 3.73 | Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. ( Nishino, T; Oyama, H; Shimizu, K; Shiratori, K; Toki, F, 2006) |
| "Sirolimus is an effective and safe treatment option for refractory CTD-TP patients." | 3.01 | Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. ( Li, M; Wang, Q; Wu, C; Xu, D; Zeng, X, 2021) |
| "Initial dosage of prednisolone was 15." | 2.69 | Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. ( Matoba, K; Miyawaki, S; Nishiyama, S, 1999) |
| "Despite restarting olanzapine, her visual hallucinations persisted." | 2.50 | Psychiatric manifestations of primary Sjögren's syndrome: a case report and literature review. ( Andrews, T; D'Cruz, D; Nortley, R; Wong, JK, 2014) |
| "Tacrolimus was discontinued." | 2.48 | Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature. ( Imai, H; Komatsu, N; Nakamura, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Wakabayashi, M, 2012) |
| "Annular erythema has been recognized to be a specific, cutaneous manifestation associated with Sjögren's syndrome." | 2.46 | Annular erythema associated with Sjögren's syndrome: review of the literature on the management and clinical analysis of skin lesions. ( Katayama, I; Kiyohara, E; Kotobuki, Y; Murota, H, 2010) |
| "We report a case of subacute transverse myelitis associated with Sjögren's syndrome free of xerosis." | 2.41 | [A case of Sjögren's syndrome with subacute transverse myelitis as the initial manifestation]. ( Arai, C; Furutani, R; Ushiyama, M, 2002) |
| "In the first case the bullae decreased in size with corticosteroid treatment." | 2.41 | Two cases of Sjögren's syndrome with multiple bullae. ( Ando, M; Kohrogi, H; Saita, N; Sakamoto, O; Suga, M, 2002) |
| "A diagnosis of transverse myelitis and peripheral neuropathy presenting as neurologic manifestations of SS was made." | 2.40 | [A case of primary Sjögren's syndrome accompanied by transverse myelitis]. ( Aoki, M; Goto, M; Inada, S; Ishii, M; Kaneko, Y; Nakajima, A; Suwa, A; Tanaka, K; Tsutsumino, M; Uehara, T; Yamada, T, 1998) |
| "BOOP has often been reported as a pulmonary manifestation of collagen vascular diseases, mainly rheumatoid arthritis (RA), but the association of BOOP and PM has rarely been documented." | 2.39 | Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia. ( Imasaki, T; Ishikawa, A; Ogura, T; Takahashi, T; Tanaka, S; Yoshii, A, 1996) |
| " SjS is a relatively rare immune-related adverse event that might sometimes be overlooked." | 1.56 | Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer. ( Furuta, Y; Higashi, T; Miyamoto, H; Nagaoka, K; Naito, H; Nakayama, H; Naoe, H; Tanaka, M; Yoshida, R, 2020) |
| "Investigations revealed distal renal tubular acidosis with severe metabolic bone disease as an extra-glandular manifestation of primary SS." | 1.56 | Primary Sjogren's syndrome manifesting with distal renal tubular acidosis and severe metabolic bone disease. ( Bhandari, S; Jain, G; Kalra, S; Vasnik, G, 2020) |
| "She had been followed up as mixed connective tissue disease and Sjögren's syndrome for over 19 years." | 1.48 | Emergence of Smoldering ANCA-associated Glomerulonephritis during the Clinical Course of Mixed Connective Tissue Disease and Sjögren's Syndrome. ( Asako, K; Fujigaki, Y; Kikuchi, H; Kondo, F; Kono, H; Morimoto, C; Ota, T; Shibata, S; Tamura, Y; Uchida, S; Yamaguchi, Y, 2018) |
| "Renal biopsy revealed tubulointerstitial nephritis with a mild focal infiltration of lymphocytes and plasma cells." | 1.48 | A Case of Sjögren's Syndrome Complicated with Interstitial Nephritis and Delayed Onset Autoimmune Hepatitis. ( Arai, T; Atsukawa, M; Fukui, M; Itokawa, N; Kashiwagi, T; Shimizu, A; Tsuruoka, S; Yamada, T, 2018) |
| "Castleman disease is a rare cause of lymphoid hyperplasia and may result in localized symptoms or an aggressive, multisystem disorder." | 1.48 | Sjögren's and plasma cell variant Castleman disease: a case report. ( Abrahams, AD; Dei-Adomakoh, YA; Dey, DI; Quarcoopome, L; Segbefia, CI, 2018) |
| "Primary lymph node plasmacytoma is a rare disease that typically involves lymph nodes of the neck." | 1.46 | Unusual course of generalized lymph node primary plasmacytoma in a patient with Sjögren's syndrome: a case report. ( Gorodetskiy, VR; Probatova, NA; Vasilyev, VI, 2017) |
| "Corticosteroid therapy remains the main treatment for systemic lupus erythematosus." | 1.46 | [Severe Interstitial Lung Disease and Manic Symptoms Secondary to Corticosteroids in a Patient with Systemic Lupus Erythematosus and Secondary Sjögren's Syndrome]. ( Branco, JC; Falcão, S; Pedrosa, T; Serra, SS, 2017) |
| "We report a case of interstitial cystitis (IC) associated with primary Sjögren's syndrome (SS) successfully controlled with combination therapy of tacrolimus and a corticosteroid." | 1.43 | Interstitial cystitis associated with primary Sjögren's syndrome successfully treated with a combination of tacrolimus and corticosteroid: A case report and literature review. ( Kaneko, H; Kano, T; Mimori, A; Takahashi, H; Takahashi, Y; Tomoe, H; Ueda, Y; Yamashita, H, 2016) |
| "He was diagnosed with autoimmune hepatitis, polymyositis and Sjögren's syndrome and received combined antiretroviral therapy (cART); however, the laboratory abnormalities persisted." | 1.42 | Corticoid therapy for overlapping syndromes in an HIV-positive patient. ( Higuchi, M; Kaieda, T; Kaku, Y; Kodama, S; Minami, R; Miyamura, T; Nakamura, A; Nakamura, M; Suematsu, E; Takahama, S; Yamamoto, M, 2015) |
| "By 24 months, renal tubular acidosis was improved and the bone density had normalized." | 1.39 | Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. ( Hirata, S; Inokuchi, N; Mori, H; Okada, Y; Saito, K; Tanaka, Y; Yamamoto, S, 2013) |
| "Recurrent parotitis is an acute, severe inflammation of one or both parotid glands, the major salivary glands in young children." | 1.37 | Recurrent parotitis as a first manifestation in a child with primary Sjogren's syndrome. ( Alp, H; Erdogan, T; Gursan, N; Karabag, K; Orbak, Z, 2011) |
| "We report a first case of severe autoimmune hemolytic anemia caused by warm reactive IgM antibodies in primary Sjögren's syndrome." | 1.36 | Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjögren's syndrome. ( Hounoki, H; Ogawa, R; Shinoda, K; Sugiyama, E; Taki, H; Tobe, K, 2010) |
| "Glomeruloid hemangioma is a specific marker of POEMS syndrome and is related to Castleman's disease." | 1.35 | Glomeruloid hemangioma. ( Shikata, N; Takasu, K; Tsubura, A; Yamazaki, F; Yuri, T, 2008) |
| "A 54-year-old female was diagnosed as mixed connective tissue disease (MCTD) complicated with secondary Sjögren's syndrome." | 1.35 | A case of mixed connective tissue disease complicated with hypertrophic obstructive cardiomyopathy. ( Ashizawa, N; Eguchi, K; Fukuda, T; Hayashi, T; Ida, H; Kawakami, A; Koide, Y; Nakamura, H; Sasaki, M; Sato, S; Seto, S; Tateishi, S, 2008) |
| "Due to secondary myelofibrosis accompanied by Sjögren syndrome, she was started on prednisolone (PSL) and recovered completely from the anemia and thrombocytopenia." | 1.34 | [Successful treatment with prednisolone for autoimmune myelofibrosis accompanied with Sjögren syndrome]. ( Hattori, N; Maeda, T; Nakamaki, T; Nakashima, H; Tomoyasu, S; Usui, T; Yanagisawa, K, 2007) |
| "NK lymphocytosis is rarely associated with autoimmune disease, but the combination of indomethacin and steroid therapy may have a favorable effect for such patients." | 1.34 | Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil. ( Fujii, T; Fujita, Y; Mimori, T; Takeda, N; Tanaka, M, 2007) |
| "Sjogren's syndrome and ankylosing spondylitis can occur either alone or in conjunction with other disorders." | 1.33 | Coexisting ankylosing spondylitis and Sjogren's syndrome: a case report. ( Cakirbay, H; Capkin, E; Guler, M; Karkucak, M; Topbas, M; Tosun, M, 2005) |
| "Treatment with prednisolone quickly brought remission of systemic and laryngeal symptoms as well as improvement in the results of video-laryngostroboscopic tests." | 1.33 | Cricoarytenoid arthritis in Sjögren's syndrome. ( Broussolle, C; Bui-Xuan, C; Charhon, A; Poupart, M; Sève, P, 2005) |
| "Pericarditis is seen in half of patients with SSc and rarely with SjS, and is usually asymptomatic." | 1.33 | [A case of systemic sclerosis and Sjogren's syndrome with cardiac tamponade due to steroid-responsive pericarditis]. ( Akiyama, O; Hagiwara, K; Kobayashi, S; Oominami, SY; Sato, T; Souma, T, 2006) |
| "Two were complicated with primary biliary cirrhosis (PBC) and autoimmune thyroiditis, whereas the other was complicated with interstitial pneumonia, but not with either PBC or autoimmune thyroiditis." | 1.33 | [Three patients with nephrotic syndrome due to membranous nephropathy complicated by Sjögren's syndrome]. ( Baba, A; Eto, T; Fujimoto, S; Hara, S; Sato, Y; Yamada, K, 2005) |
| "Severe pulmonary hypertension is one of the fetal complications in various connective tissue diseases." | 1.32 | Severe pulmonary hypertension associated with primary Sjögren's syndrome. ( Ide, H; Kikuchi, K; Nakagawa, N; Nakano, H; Nishigaki, Y; Obata, H; Ohsaki, Y; Osanai, S; Takahashi, S; Tokusashi, Y, 2003) |
| "She was diagnosed as primary biliary cirrhosis (PBC) associated with subclinical Sjögren syndrome (SjS)." | 1.32 | Prurigo pigmentosa in a patient with primary biliary cirrhosis and Sjögren syndrome. ( Shinkai, H; Togawa, Y; Utani, A, 2004) |
| "This case suggests that when severe interstitial cystitis is associated with Sjögren's syndrome, a therapeutic trial of corticosteroids and cyclosporin may be beneficial." | 1.32 | Severe interstitial cystitis associated with Sjögren's syndrome. ( Fujii, A; Hara, S; Hosino, J; Katori, H; Murata, H; Nishi, T; Sawa, N; Shibata, S; Tagami, T; Takaichi, K; Takemoto, F; Ubara, Y; Yokota, M, 2004) |
| "Systemic panniculitis is a rare complication in SS, and the pathogenesis is unclear." | 1.31 | [Case of subcutaneous and mesenteric acute panniculitis with Sjögren's syndrome]. ( Hagiyama, H; Kohsaka, H; Koike, R; Kubota, T; Miyasaka, N; Nagasaka, K; Nanki, T; Nishio, J; Nonomura, Y; Nosaka, Y; Ogawa, J; Sugihara, T, 2002) |
| "Treatment with prednisolone resulted in marked improvement of biochemical, hematological and dermatological abnormalities." | 1.31 | Autoimmune hepatitis concomitant with hypergammaglobulinemic purpura, immune thrombocytopenia, and Sjögren's syndrome. ( Kamimoto, H; Nakasho, K; Park, SY; Shintani, S; Wada, M, 2001) |
| "We report a patient with a myelopathy in primary Sjögren's syndrome, proven by salivary gland biopsy and specific antibodies." | 1.31 | Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects. ( Hermisson, M; Klein, R; Küker, W; Schmidt, F; Weller, M, 2002) |
| "She also began to notice dizziness (orthostatic hypotension) during the last 5 years." | 1.30 | [Peripheral neuropathy and dysautonomia in a patient with primary Sjögren's syndrome]. ( Chikazawa, H; Hashimoto, K; Nishiya, K, 1998) |
| "When prednisolone was gradually tapered to the dose of 30 mg per day, she was transferred to our department because of high grade fever and pancytopenia." | 1.30 | [A case of Sjögren's syndrome with retrobulbar optic neuritis and cutaneous vasculitis]. ( Ideguchi, H; Ishigatsubo, Y; Nagaoka, S; Ohkubo, T; Ohno, S; Oketani, M; Sasaki, T; Shirai, A, 1999) |
| "Prednisolone was given (60 m/day), and the symptoms and the abnormality on the chest roentgenogram resolved within about 1 month." | 1.29 | [Primary Sjögren's syndrome accompanied by pleural effusion]. ( Kashiwabara, K; Kiguchi, T; Kishi, K; Kusama, H; Matsuoka, K; Nakamura, H; Narushima, K; Syohda, S; Yagyu, H, 1995) |
| "He had a previous history of selective IgA deficiency and ulcerative colitis treated with sulphasalazine." | 1.29 | Primary Sjögren's syndrome, ulcerative colitis and selective IgA deficiency. ( Colaco, CB; McCrea, DJ; Steuer, A, 1996) |
| "Here we also discuss the treatment of thymoma and the combination of these two diseases." | 1.29 | [Sjögren's syndrome complicated by thymoma]. ( Iwai, Y; Kageshita, T; Kajiura, Y; Matsubara, M; Nakata, H; Nishimura, Y; Terashima, M; Yokoyama, M, 1996) |
| "It was increased in the active cases of systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)." | 1.28 | Serum level of interferon-gamma in autoimmune diseases. ( Funauchi, M; Horiuchi, A; Minoda, M; Sugishima, H, 1991) |
| "Treatment with prednisolone brought relief." | 1.28 | Endobronchial pseudolymphoma associated with Sjögren's syndrome. Report of a case. ( Kajiki, A; Kido, M; Kuroiwa, A; Miyazaki, N; Yamazaki, H; Yoashihara, S, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (12.92) | 18.7374 |
| 1990's | 46 (22.01) | 18.2507 |
| 2000's | 70 (33.49) | 29.6817 |
| 2010's | 58 (27.75) | 24.3611 |
| 2020's | 8 (3.83) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, Y | 1 |
| Otsuka, Y | 1 |
| Katsuyama, T | 1 |
| Nishimura, Y | 2 |
| Oka, K | 1 |
| Hasegawa, K | 2 |
| Hagiya, H | 2 |
| Otsuka, F | 2 |
| Kamogawa, Y | 1 |
| Akita, K | 1 |
| Sato, H | 1 |
| Shirai, T | 1 |
| Ishii, T | 1 |
| Harigae, H | 1 |
| Fujii, H | 2 |
| Basheer, A | 1 |
| Khan, EA | 1 |
| Hashmi, T | 1 |
| Khan, RA | 1 |
| Ahmad, A | 1 |
| Kodama, T | 1 |
| Yamazaki, Y | 1 |
| Takeo, H | 1 |
| Limaye, VS | 1 |
| Cash, K | 1 |
| Smith, C | 1 |
| Koszyca, B | 1 |
| Patel, S | 1 |
| Greenberg, SA | 1 |
| Hissaria, P | 1 |
| Jain, G | 1 |
| Kalra, S | 1 |
| Vasnik, G | 1 |
| Bhandari, S | 1 |
| Xu, J | 1 |
| Yang, Y | 1 |
| Chen, D | 1 |
| Lu, Z | 1 |
| Ge, J | 1 |
| Li, X | 1 |
| Gao, X | 1 |
| Higashi, T | 1 |
| Miyamoto, H | 1 |
| Yoshida, R | 1 |
| Furuta, Y | 1 |
| Nagaoka, K | 1 |
| Naoe, H | 1 |
| Naito, H | 1 |
| Nakayama, H | 1 |
| Tanaka, M | 3 |
| Iwata, N | 1 |
| Tomiita, M | 1 |
| Kobayashi, I | 1 |
| Inoue, Y | 1 |
| Nonaka, Y | 1 |
| Okamoto, N | 1 |
| Umebayashi, H | 1 |
| Hara, R | 1 |
| Ito, Y | 1 |
| Sato, Y | 3 |
| Mori, M | 1 |
| Wu, C | 1 |
| Wang, Q | 1 |
| Xu, D | 1 |
| Li, M | 1 |
| Zeng, X | 2 |
| Gorodetskiy, VR | 1 |
| Probatova, NA | 1 |
| Vasilyev, VI | 1 |
| Serra, SS | 1 |
| Pedrosa, T | 1 |
| Falcão, S | 1 |
| Branco, JC | 1 |
| Kawazoe, M | 1 |
| Kaneko, K | 1 |
| Shikano, K | 1 |
| Kusunoki, N | 1 |
| Nanki, T | 2 |
| Kawai, S | 1 |
| Koga, Y | 1 |
| Uchiyama Md, K | 1 |
| Tsukamoto Md PhD, N | 1 |
| Shibusawa Md PhD, N | 1 |
| Utsugi Md PhD, M | 1 |
| Kakizaki Md PhD, S | 1 |
| Hirato Md PhD, J | 1 |
| Dobashi Md PhD, K | 1 |
| Hisada Md PhD, T | 1 |
| Yamada Md PhD, M | 1 |
| Tomimatsu, T | 1 |
| Hazama, Y | 1 |
| Takeuchi, M | 1 |
| Kimura, T | 1 |
| Shimoya, K | 1 |
| Chen, FY | 1 |
| Lee, A | 1 |
| Ge, S | 1 |
| Nathan, S | 1 |
| Knox, SM | 1 |
| McNamara, NA | 1 |
| Nakano, Y | 1 |
| Yamamoto, M | 4 |
| Komatsu, K | 1 |
| Yagita, M | 1 |
| Fujita, M | 1 |
| Miyagawa, F | 1 |
| Asada, H | 1 |
| Morimoto, C | 1 |
| Fujigaki, Y | 1 |
| Tamura, Y | 1 |
| Ota, T | 1 |
| Shibata, S | 2 |
| Asako, K | 1 |
| Kikuchi, H | 1 |
| Kono, H | 1 |
| Kondo, F | 1 |
| Yamaguchi, Y | 2 |
| Uchida, S | 1 |
| Fujimoto, S | 4 |
| Kawabata, H | 2 |
| Kurose, N | 2 |
| Kawanami-Iwao, H | 1 |
| Sakai, T | 1 |
| Kawanami, T | 2 |
| Fujita, Y | 2 |
| Fukushima, T | 2 |
| Masaki, Y | 3 |
| Yamada, T | 2 |
| Fukui, M | 1 |
| Kashiwagi, T | 1 |
| Arai, T | 1 |
| Itokawa, N | 1 |
| Atsukawa, M | 1 |
| Shimizu, A | 1 |
| Tsuruoka, S | 1 |
| Dei-Adomakoh, YA | 1 |
| Quarcoopome, L | 1 |
| Abrahams, AD | 1 |
| Segbefia, CI | 1 |
| Dey, DI | 1 |
| Jain, A | 1 |
| Srinivas, BH | 1 |
| Emmanuel, D | 1 |
| Jain, VK | 1 |
| Parameshwaran, S | 1 |
| Negi, VS | 1 |
| Yoshida, T | 1 |
| Kinjo, M | 1 |
| Nakane, S | 1 |
| Agrawal, S | 1 |
| Bharti, V | 1 |
| Jain, MN | 1 |
| Purkar, PD | 1 |
| Verma, A | 1 |
| Deshpande, AK | 1 |
| Triantafyllias, K | 1 |
| Karaiskaki, N | 1 |
| Hansen, T | 1 |
| Galle, PR | 1 |
| Schwarting, A | 1 |
| Oh, HJ | 1 |
| Mok, YM | 1 |
| Baek, MS | 1 |
| Lee, JK | 1 |
| Seo, BS | 1 |
| Kim, TH | 1 |
| Choi, KH | 2 |
| Hwang, IK | 1 |
| Ra, JE | 1 |
| Oh, YR | 1 |
| Kim, YS | 1 |
| Cho, EY | 1 |
| Kim, HC | 1 |
| Sohn, YW | 1 |
| Fegan, D | 1 |
| Glennon, MJ | 1 |
| Takahashi, T | 2 |
| Ueda, Y | 1 |
| Tomoe, H | 1 |
| Takahashi, H | 4 |
| Takahashi, Y | 1 |
| Yamashita, H | 1 |
| Kaneko, H | 1 |
| Kano, T | 1 |
| Mimori, A | 1 |
| Wong, JK | 1 |
| Nortley, R | 1 |
| Andrews, T | 1 |
| D'Cruz, D | 1 |
| Subbarayudu, B | 1 |
| Sharma, MS | 1 |
| Sreemannarayana, P | 1 |
| Lee, WS | 1 |
| Kaku, Y | 1 |
| Kodama, S | 1 |
| Higuchi, M | 1 |
| Nakamura, A | 1 |
| Nakamura, M | 1 |
| Kaieda, T | 1 |
| Takahama, S | 1 |
| Minami, R | 1 |
| Miyamura, T | 1 |
| Suematsu, E | 1 |
| Fujimoto, M | 1 |
| Ikeda, K | 1 |
| Nakamura, T | 3 |
| Iwamoto, T | 1 |
| Furuta, S | 1 |
| Nakajima, H | 2 |
| Waseda, K | 1 |
| Hanayama, Y | 1 |
| Terasaka, T | 1 |
| Kimura, K | 1 |
| Tsuzuki, T | 1 |
| Nada, T | 1 |
| Nakamura, E | 1 |
| Murakami, K | 1 |
| Kondo, E | 1 |
| Justet, A | 1 |
| Ottaviani, S | 1 |
| Dieudé, P | 1 |
| Taillé, C | 1 |
| Liao, CY | 1 |
| Chien, ST | 1 |
| Wang, CC | 1 |
| Chen, IH | 1 |
| Chiu, HW | 1 |
| Liu, MY | 1 |
| Lin, CH | 1 |
| Ben, RJ | 1 |
| Tsai, MK | 1 |
| Sterling, RA | 1 |
| Carlin, A | 1 |
| Takagi, Y | 2 |
| Sumi, M | 1 |
| Nakamura, H | 5 |
| Sato, S | 2 |
| Kawakami, A | 3 |
| Lin, YR | 1 |
| Shih, CC | 1 |
| Chen, HC | 1 |
| Chen, SJ | 1 |
| Kakimoto, K | 1 |
| Inoue, T | 1 |
| Toshina, K | 1 |
| Yorifuji, N | 1 |
| Iguchi, M | 1 |
| Fujiwara, K | 1 |
| Kojima, Y | 1 |
| Okada, T | 1 |
| Nouda, S | 1 |
| Kawakami, K | 1 |
| Abe, Y | 1 |
| Takeuchi, T | 3 |
| Egashira, Y | 1 |
| Higuchi, K | 1 |
| Izumi, Y | 1 |
| Nakaoka, K | 1 |
| Kamata, M | 1 |
| Iwanaga, N | 2 |
| Imadachi, S | 1 |
| Kurohama, H | 1 |
| Ito, M | 1 |
| Migita, K | 1 |
| Kabuto, M | 1 |
| Fujimoto, N | 1 |
| Hamaguchi, Y | 1 |
| Tanaka, T | 1 |
| Nakahara, E | 1 |
| Yagasaki, H | 1 |
| Shimozawa, K | 1 |
| Hirai, M | 1 |
| Takahashi, S | 3 |
| Zahlane, S | 1 |
| Louhab, N | 1 |
| El Mellakh, M | 1 |
| Kissani, N | 1 |
| Nguyen, M | 1 |
| Peschken, CA | 1 |
| Mugundhan, K | 1 |
| Vasif, MC | 1 |
| Prakash, G | 1 |
| Balamurugan, N | 1 |
| Sivakumar, KG | 1 |
| Bakthavatchalam, B | 1 |
| Almeida, RS | 1 |
| Oliveira, AA | 1 |
| Pego, PM | 1 |
| Abuowda, Y | 1 |
| Gaspar, I | 1 |
| Costa, JM | 1 |
| Sasaki, N | 1 |
| Baba, S | 1 |
| Itou, H | 1 |
| Kowada, K | 1 |
| Shikanai, T | 1 |
| Nakamura, Y | 1 |
| Yamauchi, K | 1 |
| Inoue, H | 2 |
| Sawai, T | 1 |
| Dong, L | 1 |
| Kitagawa, K | 1 |
| Morikawa, Y | 1 |
| Shinomura, Y | 1 |
| Imai, K | 3 |
| Saeki, T | 1 |
| Azumi, A | 1 |
| Nakada, S | 1 |
| Sugiyama, E | 3 |
| Matsui, S | 2 |
| Origuchi, T | 2 |
| Nishiyama, S | 3 |
| Nishimori, I | 1 |
| Nojima, T | 1 |
| Yamada, K | 3 |
| Kawano, M | 2 |
| Zen, Y | 1 |
| Kaneko, M | 1 |
| Miyazaki, K | 1 |
| Tsubota, K | 1 |
| Eguchi, K | 4 |
| Tomoda, K | 1 |
| Sawaki, T | 1 |
| Sugai, S | 3 |
| Umehara, H | 1 |
| Min, JH | 1 |
| Youn, YC | 1 |
| Yamauchi, N | 1 |
| Muramatsu, H | 1 |
| Inomata, H | 1 |
| Numata, T | 1 |
| Nozawa, E | 1 |
| Nishino, M | 1 |
| Koyama, R | 1 |
| Ihara, K | 1 |
| Nishisato, T | 1 |
| Hirayama, M | 1 |
| Katsuki, S | 1 |
| Matsunaga, T | 1 |
| Niitsu, Y | 1 |
| Yaguchi, H | 1 |
| Houzen, H | 1 |
| Kikuchi, K | 2 |
| Hata, D | 1 |
| Ura, S | 1 |
| Takeda, T | 2 |
| Yabe, I | 1 |
| Sasaki, H | 1 |
| Adzić, TN | 1 |
| Stojsić, JM | 1 |
| Radosavljević-Asić, GD | 1 |
| Bouros, D | 1 |
| Kondo, T | 1 |
| Usui, T | 2 |
| Mimori, T | 3 |
| Tomimoto, H | 1 |
| Vernino, S | 1 |
| Takahashi, R | 1 |
| Shi, JH | 1 |
| Liu, HR | 1 |
| Xu, WB | 1 |
| Feng, RE | 1 |
| Zhang, ZH | 1 |
| Tian, XL | 1 |
| Zhu, YJ | 1 |
| Katayama, I | 3 |
| Kotobuki, Y | 1 |
| Kiyohara, E | 1 |
| Murota, H | 1 |
| Möller, J | 1 |
| Girschick, HJ | 1 |
| Hahn, G | 1 |
| Pessler, F | 1 |
| Imbe, H | 1 |
| Ito, T | 1 |
| Kitaoka, H | 1 |
| Ito, S | 2 |
| Kamei, K | 1 |
| Ikoma, M | 1 |
| Shinoda, K | 1 |
| Taki, H | 1 |
| Hounoki, H | 1 |
| Ogawa, R | 1 |
| Tobe, K | 1 |
| Saito, S | 1 |
| Togashi, A | 1 |
| Kaneko, F | 1 |
| Yamamoto, T | 2 |
| Uchida, T | 1 |
| Oyama, N | 1 |
| Efthimiou, P | 1 |
| Kukar, M | 1 |
| Hersh, A | 1 |
| Hasiloglu, ZI | 1 |
| Albayram, S | 1 |
| Tasmali, K | 1 |
| Erer, B | 1 |
| Selcuk, H | 1 |
| Islak, C | 1 |
| Naniwa, T | 1 |
| Takeda, Y | 1 |
| Kamath, V | 1 |
| Prabhakar, B | 1 |
| Lachikarathman, D | 1 |
| Yasuda, K | 1 |
| Sasaki, K | 1 |
| Yamato, M | 1 |
| Hayashi, T | 2 |
| Asashima, H | 1 |
| Inokuma, S | 1 |
| Nakachi, S | 1 |
| Matsuo, Y | 1 |
| Rokutanda, R | 1 |
| Hagiwara, K | 2 |
| Kobayashi, S | 3 |
| Alp, H | 1 |
| Orbak, Z | 1 |
| Erdogan, T | 1 |
| Karabag, K | 1 |
| Gursan, N | 1 |
| Yamamoto, S | 2 |
| Okada, Y | 1 |
| Mori, H | 2 |
| Hirata, S | 1 |
| Saito, K | 1 |
| Inokuchi, N | 1 |
| Tanaka, Y | 1 |
| Wu, TJ | 1 |
| Yan, MT | 1 |
| Chau, T | 1 |
| Lin, SH | 1 |
| Sekiguchi, Y | 1 |
| Shimada, A | 1 |
| Imai, H | 1 |
| Wakabayashi, M | 1 |
| Sugimoto, K | 1 |
| Nakamura, N | 1 |
| Sawada, T | 1 |
| Komatsu, N | 1 |
| Noguchi, M | 1 |
| Gao, LX | 1 |
| Zhang, FC | 1 |
| Wang, L | 1 |
| Zhang, X | 2 |
| Liu, B | 1 |
| Odaka, H | 1 |
| Kiso, K | 1 |
| Watanabe, K | 1 |
| Obata, A | 1 |
| Miyamuma, H | 1 |
| Muryoi, T | 1 |
| Casis, B | 1 |
| Fernández-Vázquez, I | 1 |
| Barnardos, E | 1 |
| Saiz, A | 1 |
| Ballestín, C | 1 |
| Morillas, JD | 1 |
| Colina, F | 1 |
| Solís-Herruzo, JA | 1 |
| Tekeli, O | 1 |
| Ozdemir, O | 1 |
| Martínez-Salio, A | 1 |
| Penas, M | 1 |
| Porta-Etessam, J | 1 |
| Lizasoain, M | 1 |
| Gyulai, R | 1 |
| Kiss, M | 1 |
| Mehravaran, M | 1 |
| Kovács, L | 1 |
| Pokorny, G | 1 |
| Husz, S | 1 |
| Dobozy, A | 1 |
| Arai, C | 1 |
| Furutani, R | 1 |
| Ushiyama, M | 1 |
| Edrees, A | 1 |
| Tran, J | 1 |
| Thompson, G | 1 |
| Watson, KR | 1 |
| Godfrey, W | 1 |
| Abdou, NI | 1 |
| Nagaoka, M | 1 |
| Tamaoki, J | 1 |
| Gotoh, S | 1 |
| Nakazawa, H | 1 |
| Nagai, A | 1 |
| Komatsu, H | 1 |
| Hara, S | 3 |
| Kikuchi, M | 1 |
| Matsumoto, M | 1 |
| Eto, T | 2 |
| Choi, YM | 1 |
| Sheen, DH | 1 |
| Lee, YJ | 1 |
| Lee, EB | 1 |
| Song, YW | 1 |
| Kondo, H | 1 |
| Nakagawa, N | 1 |
| Osanai, S | 1 |
| Ide, H | 1 |
| Nishigaki, Y | 1 |
| Nakano, H | 1 |
| Ohsaki, Y | 1 |
| Tokusashi, Y | 1 |
| Obata, H | 1 |
| Kitagawa, Y | 1 |
| Mitsushima, H | 1 |
| Kawazoe, K | 1 |
| Takahashi, A | 1 |
| Oishi, K | 1 |
| Nagatake, T | 1 |
| Ubara, Y | 1 |
| Sawa, N | 1 |
| Tagami, T | 1 |
| Hosino, J | 1 |
| Yokota, M | 1 |
| Katori, H | 1 |
| Takemoto, F | 1 |
| Takaichi, K | 1 |
| Fujii, A | 1 |
| Murata, H | 1 |
| Nishi, T | 1 |
| Tanaka, H | 2 |
| Abe, T | 2 |
| Nishimura, S | 1 |
| Sakai, H | 1 |
| Kimura, H | 1 |
| Oki, M | 1 |
| Nojima, M | 1 |
| Taga, M | 1 |
| Matsumoto, S | 1 |
| Alchi, B | 1 |
| Sekiguchi, T | 1 |
| Ogino, S | 1 |
| Nishi, S | 1 |
| Ueno, M | 1 |
| Gejyo, F | 1 |
| Sève, P | 1 |
| Poupart, M | 1 |
| Bui-Xuan, C | 1 |
| Charhon, A | 1 |
| Broussolle, C | 1 |
| Muro, Y | 1 |
| Tomita, Y | 1 |
| Togawa, Y | 1 |
| Shinkai, H | 2 |
| Utani, A | 1 |
| Tosun, M | 1 |
| Karkucak, M | 1 |
| Capkin, E | 1 |
| Cakirbay, H | 1 |
| Guler, M | 1 |
| Topbas, M | 1 |
| Azuma, N | 1 |
| Katada, Y | 1 |
| Harada, Y | 1 |
| Arimoto, H | 1 |
| Kimura, Y | 1 |
| Terada, H | 1 |
| Tsujino, K | 1 |
| Kida, H | 1 |
| Kudo, E | 1 |
| Umeshita, M | 1 |
| Mima, T | 1 |
| Saeki, Y | 1 |
| Baba, A | 1 |
| Chen, HA | 1 |
| Lai, SL | 1 |
| Kwang, WK | 1 |
| Liu, JC | 1 |
| Chen, CH | 1 |
| Huang, DF | 1 |
| Sugihara, T | 1 |
| Koike, R | 1 |
| Nosaka, Y | 1 |
| Ogawa, J | 1 |
| Hagiyama, H | 1 |
| Nagasaka, K | 1 |
| Nonomura, Y | 1 |
| Nishio, J | 1 |
| Kohsaka, H | 1 |
| Kubota, T | 1 |
| Miyasaka, N | 1 |
| Nishino, T | 1 |
| Toki, F | 1 |
| Oyama, H | 1 |
| Shimizu, K | 1 |
| Shiratori, K | 1 |
| Sato, T | 1 |
| Oominami, SY | 1 |
| Souma, T | 1 |
| Akiyama, O | 1 |
| Fujii, T | 1 |
| Takeda, N | 1 |
| Ishida, K | 1 |
| Uchihara, T | 1 |
| Mizusawa, H | 1 |
| Yoshida, K | 1 |
| Yokoyama, T | 1 |
| Toyokawa, Y | 1 |
| Yasuda, J | 1 |
| Kingetsu, I | 1 |
| Kurosaka, D | 1 |
| Yamada, A | 1 |
| Mutsukura, K | 1 |
| Ida, H | 2 |
| Furuyama, M | 1 |
| Makino, S | 1 |
| Yonemoto, H | 1 |
| Itoh, S | 1 |
| Takeda, S | 1 |
| Fernandes, M | 1 |
| Vemuganti, GK | 1 |
| Rao, GN | 1 |
| Sumida, T | 2 |
| Shimoyama, K | 1 |
| Ogawa, N | 2 |
| Dei, Y | 1 |
| Suzuki, D | 1 |
| Saito, M | 1 |
| Hayashi, H | 2 |
| Hattori, N | 1 |
| Nakashima, H | 1 |
| Maeda, T | 1 |
| Yanagisawa, K | 1 |
| Nakamaki, T | 1 |
| Tomoyasu, S | 1 |
| Devauchelle-Pensec, V | 1 |
| Pers, JO | 1 |
| Youinou, P | 1 |
| Saraux, A | 1 |
| Yuri, T | 1 |
| Yamazaki, F | 1 |
| Takasu, K | 1 |
| Shikata, N | 1 |
| Tsubura, A | 1 |
| Kobayashi, T | 1 |
| Hatamochi, A | 1 |
| Kamada, N | 1 |
| Matsue, H | 1 |
| Yukawa, S | 1 |
| Tahara, K | 1 |
| Yukawa, N | 1 |
| Shoji, A | 1 |
| Tsuji, S | 1 |
| Tsuboi, N | 1 |
| Tateishi, S | 1 |
| Fukuda, T | 1 |
| Sasaki, M | 1 |
| Koide, Y | 1 |
| Ashizawa, N | 1 |
| Seto, S | 1 |
| Hull, RG | 1 |
| Morgan, SH | 1 |
| Harding, AE | 1 |
| Hughes, GR | 1 |
| Inoh, M | 1 |
| Tokuda, M | 1 |
| Maruoka, T | 1 |
| Kinashi, M | 1 |
| Kurata, N | 1 |
| Okawa, M | 1 |
| Takahara, J | 1 |
| Schnabel, A | 1 |
| Brahma, AK | 1 |
| Hay, E | 1 |
| Sturgess, DA | 1 |
| Morgan, LH | 1 |
| Nishimura, H | 1 |
| Tachibana, H | 1 |
| Makiura, N | 1 |
| Okuda, B | 1 |
| Sugita, M | 1 |
| Ishimaru, S | 1 |
| Izaki, S | 1 |
| Kitamura, K | 1 |
| Morita, Y | 1 |
| Bijl, M | 1 |
| Panders, AK | 1 |
| Vissink, A | 1 |
| Nikkels, PG | 1 |
| Kallenberg, CG | 1 |
| Gerraty, RP | 1 |
| McKelvie, PA | 1 |
| Byrne, E | 1 |
| Kawashima, N | 1 |
| Shindo, R | 1 |
| Kohno, M | 1 |
| Lafforgue, P | 1 |
| Toussirot, E | 1 |
| Billé, F | 1 |
| Acquaviva, PC | 1 |
| Ohtsuka, T | 1 |
| Saito, Y | 1 |
| Hasegawa, M | 1 |
| Tatsuno, M | 1 |
| Takita, S | 1 |
| Arita, M | 1 |
| Okuyama, K | 1 |
| Kashiwabara, K | 1 |
| Kishi, K | 1 |
| Narushima, K | 1 |
| Yagyu, H | 1 |
| Kiguchi, T | 1 |
| Syohda, S | 1 |
| Kusama, H | 1 |
| Matsuoka, K | 1 |
| Sakai, I | 1 |
| Taneichi, K | 1 |
| Shibaki, H | 1 |
| Imasaki, T | 1 |
| Yoshii, A | 1 |
| Tanaka, S | 1 |
| Ogura, T | 1 |
| Ishikawa, A | 1 |
| Steuer, A | 1 |
| McCrea, DJ | 1 |
| Colaco, CB | 1 |
| Matsumura, R | 1 |
| Kagami, M | 1 |
| Tomioka, H | 1 |
| Sugiyama, T | 1 |
| Sueishi, M | 1 |
| Terashima, M | 1 |
| Kageshita, T | 1 |
| Kajiura, Y | 1 |
| Nakata, H | 1 |
| Matsubara, M | 1 |
| Iwai, Y | 1 |
| Yokoyama, M | 1 |
| Yokoyama, A | 1 |
| Konishi, M | 1 |
| Ohosone, Y | 1 |
| Matsumura, M | 1 |
| Oyamada, Y | 1 |
| Yamaguchi, K | 1 |
| Kawahara, Y | 1 |
| Ikeda, Y | 1 |
| Osawa, H | 1 |
| Yamabe, H | 1 |
| Seino, S | 1 |
| Fukushi, K | 1 |
| Miyata, M | 1 |
| Inuma, H | 1 |
| Kaizuka, M | 1 |
| Tamura, N | 1 |
| Tsunoda, S | 2 |
| Baba, Y | 1 |
| Shirato, K | 1 |
| Onodera, K | 1 |
| Hanada, K | 1 |
| Mochizuki, H | 2 |
| Okano, M | 1 |
| Masaki, T | 3 |
| Nagata, N | 1 |
| Kamakura, K | 2 |
| Hirata, Y | 1 |
| Takizawa, H | 1 |
| Okazaki, H | 1 |
| Yoshida, A | 1 |
| Ishii, A | 1 |
| Kohno, T | 1 |
| Nakajima, J | 1 |
| Oka, T | 1 |
| Ito, K | 1 |
| Tanaka, N | 1 |
| Nakano, T | 1 |
| Isshiki, K | 1 |
| Nagato, Y | 1 |
| Tsujie, M | 1 |
| Nakayama, Y | 1 |
| Kakihara, M | 1 |
| Yamada, Y | 1 |
| Kamata, T | 1 |
| Abe, H | 1 |
| Ohana, M | 1 |
| Okazaki, K | 1 |
| Hajiro, K | 1 |
| Kobashi, Y | 1 |
| Rojas-Rodriguez, J | 1 |
| Garcia-Carrasco, M | 1 |
| Ramirez, ES | 1 |
| Romero-Rodriguez, F | 1 |
| Ramos-Casals, M | 1 |
| Rojas-Serrano, J | 1 |
| Terrazas-Ramirez, A | 1 |
| Hisahara, S | 1 |
| Ohkoshi, N | 1 |
| Shoji, S | 1 |
| Muro, K | 1 |
| Yamaguchi, N | 1 |
| Kobayashi, M | 2 |
| Koyama, A | 1 |
| Usui, K | 1 |
| Anzai, C | 1 |
| Sano, K | 1 |
| Kumazaki, S | 1 |
| Ishihara, T | 1 |
| Yamanouchi, J | 1 |
| Yokota, E | 1 |
| Yamauchi, Y | 2 |
| Matsumoto, I | 1 |
| Kaneko, Y | 1 |
| Suwa, A | 1 |
| Nakajima, A | 1 |
| Ishii, M | 1 |
| Aoki, M | 1 |
| Tsutsumino, M | 1 |
| Goto, M | 1 |
| Uehara, T | 1 |
| Tanaka, K | 1 |
| Inada, S | 1 |
| Izumi, M | 1 |
| Kawabe, Y | 1 |
| Chikazawa, H | 1 |
| Nishiya, K | 1 |
| Hashimoto, K | 1 |
| Onodera, N | 1 |
| Ito, R | 1 |
| Higuchi, A | 1 |
| Suzuki, Y | 2 |
| Monma, N | 1 |
| Waga, S | 1 |
| Tholl, U | 1 |
| Hartung, K | 1 |
| Helmchen, U | 1 |
| Anlauf, M | 1 |
| Yamada, H | 1 |
| Kato, EH | 1 |
| Ebina, Y | 1 |
| Moriwaki, M | 1 |
| Yamamoto, R | 1 |
| Furuta, I | 1 |
| Miyawaki, S | 1 |
| Matoba, K | 1 |
| Peris, P | 1 |
| Font, J | 1 |
| Grau, JM | 1 |
| Martínez de Osaba, MJ | 1 |
| Filella, X | 1 |
| Muñoz-Gómez, J | 1 |
| Katayama, Y | 2 |
| Kohriyama, K | 2 |
| Kirizuka, K | 1 |
| Nishizaki, H | 1 |
| Tanji, Y | 1 |
| Oketani, M | 1 |
| Ideguchi, H | 1 |
| Ohkubo, T | 1 |
| Ohno, S | 2 |
| Shirai, A | 1 |
| Sasaki, T | 1 |
| Nagaoka, S | 1 |
| Ishigatsubo, Y | 1 |
| Koni, I | 1 |
| Kasahara, Y | 1 |
| Yachie, A | 1 |
| Miyawaki, T | 1 |
| Seki, H | 1 |
| Mizukoshi, T | 1 |
| Murakami, R | 1 |
| Tokuno, T | 1 |
| Makiguchi, Y | 1 |
| Ideura, H | 1 |
| Tsukada, Y | 1 |
| Maezawa, A | 1 |
| Ueki, K | 1 |
| Nojima, Y | 1 |
| Naruse, T | 1 |
| Hent, RC | 1 |
| Bergkamp, FJ | 1 |
| Weening, JJ | 1 |
| Schut, NH | 1 |
| Sakurai, M | 1 |
| Hayashi, K | 1 |
| Nemoto, A | 1 |
| Yamauti, M | 1 |
| Morris-Jones, R | 1 |
| Walker, M | 1 |
| Hardman, C | 1 |
| Maeda, A | 1 |
| Yamanouchi, H | 1 |
| Lee, JB | 1 |
| Tanaka, A | 1 |
| Tohda, Y | 1 |
| Fukuoka, M | 1 |
| Nakajima, S | 1 |
| Hayashi, R | 1 |
| Yamashita, N | 1 |
| Maruyama, M | 1 |
| Yoshida, Y | 1 |
| Arai, N | 1 |
| Ishihara, O | 1 |
| Saitoh, M | 1 |
| Hayashi, N | 1 |
| Kinoshita, K | 1 |
| Teruuchi, S | 1 |
| Bando, M | 1 |
| Hironaka, M | 1 |
| Sugiyama, Y | 1 |
| Fukumura, A | 1 |
| Simoyama, K | 1 |
| Karasawa, H | 1 |
| Okada, J | 1 |
| Kim, CG | 1 |
| Wano, Y | 1 |
| Wada, M | 1 |
| Kamimoto, H | 1 |
| Park, SY | 1 |
| Shintani, S | 1 |
| Nakasho, K | 1 |
| Sakamoto, O | 1 |
| Saita, N | 1 |
| Ando, M | 2 |
| Kohrogi, H | 1 |
| Suga, M | 1 |
| Hirata, A | 1 |
| Nakamura, R | 1 |
| Motoyoshi, K | 1 |
| Hermisson, M | 1 |
| Klein, R | 1 |
| Schmidt, F | 1 |
| Weller, M | 1 |
| Küker, W | 1 |
| Pang, M | 1 |
| Setoyama, Y | 1 |
| Tsuzaka, K | 1 |
| Yoshimoto, K | 1 |
| Amano, K | 1 |
| Török, M | 1 |
| Kincses, E | 1 |
| Achenbach, W | 1 |
| Malaviya, AN | 1 |
| Kar, A | 1 |
| Goswami, S | 1 |
| Bhuyan, UN | 1 |
| Kumar, R | 1 |
| Malhotra, KK | 1 |
| Taneja, RL | 1 |
| Nawata, Y | 1 |
| Kato, N | 1 |
| Kawanishi, K | 1 |
| Kawamura, K | 1 |
| Nishina, Y | 1 |
| Goto, A | 1 |
| Okada, S | 1 |
| Saida, K | 1 |
| Bansal, A | 1 |
| Roberts, T | 1 |
| Hay, EM | 1 |
| Kay, R | 1 |
| Pumphrey, RS | 1 |
| Wilson, PB | 1 |
| Nishizaka, Y | 1 |
| Oda, Y | 1 |
| Dohi, K | 1 |
| Morita, H | 1 |
| Funauchi, M | 1 |
| Sugishima, H | 1 |
| Minoda, M | 1 |
| Horiuchi, A | 1 |
| Yamane, K | 1 |
| Shome, GP | 1 |
| Akama, T | 1 |
| Suzuki, H | 1 |
| Matsui, Y | 1 |
| Kashiwagi, H | 1 |
| Nagao, T | 1 |
| Takagi, K | 1 |
| Hashida, H | 1 |
| Sakuta, M | 1 |
| Kamouchi, M | 1 |
| Tsuji, H | 1 |
| Hirakata, H | 1 |
| Okamura, K | 1 |
| Ishitsuka, T | 1 |
| Murai, K | 1 |
| Onoyama, K | 1 |
| Fujishima, M | 1 |
| Heathcote, JG | 1 |
| McCartney, AC | 1 |
| Rice, NS | 1 |
| Peacock, J | 1 |
| Seal, DV | 1 |
| Sato, A | 1 |
| Ida, M | 1 |
| Watanabe, H | 2 |
| Iwata, M | 1 |
| Taniguchi, M | 1 |
| Miyazaki, N | 1 |
| Kido, M | 1 |
| Kajiki, A | 1 |
| Yamazaki, H | 1 |
| Yoashihara, S | 1 |
| Kuroiwa, A | 1 |
| Teramoto, N | 1 |
| Arai, H | 1 |
| Eto, H | 1 |
| Kamimura, K | 1 |
| Uetsuka, M | 1 |
| Kondo, S | 1 |
| Nishioka, K | 1 |
| Yamashita, K | 1 |
| Yamaguchi, S | 1 |
| Tsunematsu, T | 1 |
| Talal, N | 1 |
| Tachibana, J | 1 |
| Yoshioka, R | 1 |
| Sawada, M | 1 |
| Shimizu, S | 1 |
| Hirose, Y | 1 |
| Takiguchi, T | 1 |
| Konda, S | 1 |
| Vasil'ev, VI | 1 |
| Simonova, MV | 1 |
| Safonova, TN | 1 |
| Mach, ES | 1 |
| Ivanova, AV | 1 |
| Bezuglov, MF | 1 |
| Suzuki, T | 1 |
| Yoshida, H | 1 |
| Wakashin, M | 1 |
| Okuda, K | 1 |
| Kawauchi, K | 1 |
| Sugiyama, H | 1 |
| Watanabe, S | 1 |
| Aumaitre, O | 1 |
| Pouplard-Barthelaix, A | 1 |
| Thieblot, P | 1 |
| Dordain, G | 1 |
| Moinade, S | 1 |
| Ho, CH | 1 |
| Chiang, YM | 1 |
| Chong, LL | 1 |
| Lin, HY | 1 |
| Hwang, TS | 1 |
| Job-Deslandre, C | 1 |
| Menkès, CJ | 1 |
| Brunt, MF | 1 |
| James, DG | 1 |
| Williamson, J | 1 |
| Gibson, AA | 1 |
| Wilson, T | 1 |
| Forrester, JV | 1 |
| Whaley, K | 1 |
| Dick, WC | 1 |
| Cziráki, L | 1 |
| Szemere, P | 1 |
| Stacher, A | 1 |
| Böhnel, J | 1 |
| Schindler, H | 1 |
| Seifert, E | 1 |
| Karlish, AJ | 1 |
| Singleton, MA | 1 |
| Gros, JC | 1 |
| Potiakina, NN | 1 |
| Mikanba, ZM | 1 |
| Sage, RE | 1 |
| Forbes, IJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus in Patients With Connective Tissue Disease Related Thrombocytopenia (CTD-TP): a Single-arm, Open-label Clinical Trial in China[NCT03688191] | Phase 4 | 20 participants (Anticipated) | Interventional | 2017-09-21 | Active, not recruiting | ||
| A Randomized Within-Subject, Double-Blind, Placebo-Controlled Study of Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects[NCT01316770] | Phase 2 | 14 participants (Actual) | Interventional | 2011-05-01 | Terminated (stopped due to Slow enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Saliva flow rate was determined by weighing the saliva flow collected separately from each parotid (dexamethasone irrigated and placebo irrigated parotid) within a participant and dividing by collection time. Saliva was collected using a Teflon collection cup placed over the parotid duct orifice and hel in place by slight negative pressure. Collection time was 1 minute. The outcome measure is looking at change from baseline at Study Day 28 and not the flow at any particular time. (NCT01316770)
Timeframe: Baseline to 28 days post-baseline
| Intervention | g/min (Mean) |
|---|---|
| Dexamethasone Irrigation of Parotid Gland | -0.09808 |
| Placebo Irrigation of Parotid Gland | -0.06678 |
Saliva flow rate was determined by weighing the saliva flow collected separately from each parotid (dexamethasone irrigated and placebo irrigated parotid) within a participant and dividing by collection time. Saliva was collected using a Teflon collection cup placed over the parotid duct orifice and hel in place by slight negative pressure. Collection time was 1 minute. The outcome measure is looking at change from baseline at Study Day 42 and not the flow at any particular time. (NCT01316770)
Timeframe: Baseline to 42 days post-baseline
| Intervention | g/min (Mean) |
|---|---|
| Dexamethasone Irrigation of Parotid Gland | 0.00224 |
| Placebo Irrigation of Parotid Gland | 0.01192 |
Saliva flow rate was determined by weighing the saliva flow collected separately from each parotid (dexamethasone irrigated and placebo irrigated parotid) within a participant and dividing by collection time. Saliva was collected using a Teflon collection cup placed over the parotid duct orifice and held in place by slight negative pressure. Collection time was 1 minute. The primary outcome measure is looking at change from baseline at Study Day 56 and not the flow at any particular time. (NCT01316770)
Timeframe: Baseline (Study Day 0) to Study Day 56
| Intervention | g/min (Mean) |
|---|---|
| Dexamethasone Irrigation of Parotid Gland | -0.01120 |
| Placebo Irrigation of Parotid Gland | -0.05204 |
Saliva flow rate was determined by weighing the saliva flow collected separately from each parotid (dexamethasone irrigated and placebo irrigated parotid) within a participant and dividing by collection time. Saliva was collected using a Teflon collection cup placed over the parotid duct orifice and hel in place by slight negative pressure. Collection time was 1 minute. The outcome measure is looking at change from baseline at Study Day 14 and not the flow at any particular time. (NCT01316770)
Timeframe: Baseline to 14 days post-baseline
| Intervention | g/min (Mean) |
|---|---|
| Dexamethasone Irrigation of Parotid Gland | -0.01106 |
| Placebo Irrigation of Parotid Gland | 0.01875 |
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Sip water | Baseline: Sip liquids other than water | Baseline: use commercial products | Baseline: Chew sugared gum or mints | Baseline: Chew sugarless gum or mints | Study Day 14: Sip water | Study Day 14: Sip liquids other than water | Study Day 14: use commercial products | Study Day 14: Chew sugared gum or mints | Study Day 14: Chew sugarless gum or mints | Study Day 28: Sip water | Study Day 28: Sip liquids other than water | Study Day 28: use commercial products | Study Day 28: Chew sugared gum or mints | Study Day 28: Chew sugarless gum or mints | Study Day 42: Sip water | Study Day 42: Sip liquids other than water | Study Day 42: use commercial products | Study Day 42: Chew sugared gum or mints | Study Day 42: Chew sugarless gum or mints | Study Day 56: Sip water | Study Day 56: Sip liquids other than water | Study Day 56: use commercial products | Study Day 56: Chew sugared gum or mints | Study Day 56: Chew sugarless gum or mints | |
| Overall Study | 8 | 6 | 4 | 1 | 2 | 8 | 6 | 3 | 1 | 4 | 8 | 7 | 4 | 2 | 3 | 7 | 5 | 3 | 2 | 3 | 8 | 3 | 3 | 1 | 2 |
Focus score is the number of mononuclear cell infiltrates containing at least 50 inflammatory cells in a 4 mm² glandular section. Table data are the shift in focus score from Stage II Screening to Study Day 56. Only shift table cells with more than 0 participants were included in the Outcome Measure Data Table below. (NCT01316770)
Timeframe: Stage II Screening (within 6 wks before baseline) through 56 days post-baseline
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening Focus=0; Day 56 Focus=0 | Screening Focus=1; Day 56 Focus=1 | Screening Focus=2; Day 56 Focus=0 | Screening Focus=2; Day 56 Focus=5 | Screening Focus=3; Day 56 Focus=not done | Screening Focus=12; Day 56 Focus=3 | Screening Focus=not done; Day 56 Focus=not done | |
| Dexamethasone Irrigation of Parotid Gland | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| Placebo Irrigation of Parotid Gland | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
Ordinal Scale 0: least to 10: greatest level of disease activity. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | score on a scale (Median) | ||||
|---|---|---|---|---|---|
| Baseline | Study Day 14 | Study Day 28 | Study Day 42 | Study Day 56 | |
| Overall Study | 5 | 5 | 5 | 5 | 5 |
Ordinal Scale 0:least to 10:greatest level of disease activity (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Baseline | Study Day 14 | Study Day 28 | Study Day 42 | Study Day 56 | |
| Overall Study | 5 | 5 | 5 | 5 | 5 |
Focus score is the number of mononuclear cell infiltrates containing at least 50 inflammatory cells in a 4 mm² glandular section. Focus scores ≥1 are key criteria used in the diagnosis of inflammation in the oral component of Sjögren's Syndrome. Higher numbers are associated with more inflammation. (Range 0-12). (NCT01316770)
Timeframe: Stage II screening (within 6 wks before baseline) through 56 days post-baseline
| Intervention | score on a scale (Median) | |
|---|---|---|
| Stage II Screening | Study Day 56 | |
| Dexamethasone Irrigation of Parotid Gland | 2.5 | 1 |
| Placebo Irrigation of Parotid Gland | 1.5 | 0.5 |
Possible Response: Yes or No (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||
| No | Yes | |||||||
| Overall Study | 9 | |||||||
| Overall Study | 0 | |||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56. The shift table data were not sufficiently distributed to permit analysis with McNemar's test on any of the study days. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: No; Study Day: Yes | Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 9 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56. The shift table data were not sufficiently distributed to permit analysis with McNemar's test on Study Days 42 and 56. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: No; Study Day: No | Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | |||||||||||||
| Overall Study | 7 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 8 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56 (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: Yes; Study Day: No | Screening II: Yes; Study Day: Yes | Screening II: No; Study Day: Yes | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 3 | |||||||||||||||
| Overall Study | 5 | |||||||||||||||
| Overall Study | 2 | |||||||||||||||
| Overall Study | 6 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 7 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56 (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: No; Study Day: No | Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | |||||||||||||
| Overall Study | 5 | |||||||||||||||
| Overall Study | 2 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 6 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56 (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 3 | |||||||||||||||
| Overall Study | 2 | |||||||||||||||
| Overall Study | 4 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 5 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56. The shift table data were not sufficiently distributed to permit analysis with McNemar's test on any of the study days. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 6 | |||||||||||||||
| Overall Study | 5 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56 (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: No; Study Day: Yes | Screening II: Yes; Study Day: Yes | Screening II: No; Study Day: No | Screening II: Yes; Study Day: No | |||||||||||||
| Overall Study | 6 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
| Overall Study | 7 | |||||||||||||||
Shift table with respect to the change from the Stage II Screening Visit (used as Baseline) for Study Days: 14, 28, 42, and 56. The shift table data were not sufficiently distributed to permit analysis with McNemar's test on any of the study days. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||
| Screening II: Yes; Study Day: Yes | Screening II: Yes; Study Day: No | Screening II: No; Study Day: Yes | Screening II: No; Study Day: No | |||||||||||||
| Overall Study | 8 | |||||||||||||||
| Overall Study | 0 | |||||||||||||||
| Overall Study | 1 | |||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024068 | Study Day 1472024068 | Study Day 2872024068 | Study Day 4272024068 | Study Day 5672024068 | ||||||
| Yes | No | |||||||||
| All Study Participants | 2 | |||||||||
| All Study Participants | 7 | |||||||||
| All Study Participants | 1 | |||||||||
| All Study Participants | 8 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| Yes | No | |||||||||
| Overall Study | 1 | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 6 | |||||||||
| Overall Study | 3 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 0 | |||||||||
| Overall Study | 9 | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 1 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: To little; to much; Do not notice it. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||
| Do not notice it | Too much | Too little | |||||||||||||
| Overall Study | 5 | ||||||||||||||
| Overall Study | 6 | ||||||||||||||
| Overall Study | 0 | ||||||||||||||
| Overall Study | 3 | ||||||||||||||
| Overall Study | 4 | ||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes; No; Not sure. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||
| Yes | No | Not Sure | |||||||||||||
| Overall Study | 3 | ||||||||||||||
| Overall Study | 6 | ||||||||||||||
| Overall Study | 0 | ||||||||||||||
| Overall Study | 1 | ||||||||||||||
| Overall Study | 5 | ||||||||||||||
| Overall Study | 2 | ||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes; No; Not sure. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||
| Yes | No | Not Sure | |||||||||||||
| Overall Study | 6 | ||||||||||||||
| Overall Study | 2 | ||||||||||||||
| Overall Study | 7 | ||||||||||||||
| Overall Study | 8 | ||||||||||||||
| Overall Study | 0 | ||||||||||||||
| Overall Study | 1 | ||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 2 | |||||||||
| Overall Study | 7 | |||||||||
| Overall Study | 1 | |||||||||
| Overall Study | 9 | |||||||||
| Overall Study | 0 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||||||||||||
| I have tooth pain | I have gum pain | I have pain in my jaws or TMJ | Mouth or tongue burns | |||||||||||||||||
| Overall Study | 0 | |||||||||||||||||||
| Overall Study | 1 | |||||||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||||||||||||
| Foods taste more intense (for example, more sweet) | Foods taste different than they used to | Foods taste less intense (for example, less sweet) | I have persistent bad taste in my mouth | |||||||||||||||||
| Overall Study | 1 | |||||||||||||||||||
| Overall Study | 0 | |||||||||||||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| Yes | No | |||||||||
| Overall Study | 3 | |||||||||
| Overall Study | 6 | |||||||||
| Overall Study | 1 | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 2 | |||||||||
| Overall Study | 7 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 9 | |||||||||
| Overall Study | 0 | |||||||||
The questionnaire's question is on the whole participant level rather than on the individual parotid level; thus, no treatment group comparisons are possible. Possible responses: Yes or No. (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||||||||||
| Dryness | Weakness | Other | Pain | Too few Teeth | |||||||||||||||||||||
| Overall Study | 3 | ||||||||||||||||||||||||
| Overall Study | 1 | ||||||||||||||||||||||||
| Overall Study | 0 | ||||||||||||||||||||||||
| Overall Study | 2 | ||||||||||||||||||||||||
Response: Yes; No (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72024067 | Study 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 1 | |||||||||
| Overall Study | 8 | |||||||||
| Overall Study | 7 | |||||||||
| Overall Study | 2 | |||||||||
| Overall Study | 0 | |||||||||
| Overall Study | 9 | |||||||||
Nominal Scale: Much better; Better; The same; Worse; Much worse (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||||||||||
| Better | The same | Much worse | Much better | Worse | |||||||||||||||||||||
| Overall Study | 7 | ||||||||||||||||||||||||
| Overall Study | 2 | ||||||||||||||||||||||||
| Overall Study | 9 | ||||||||||||||||||||||||
| Overall Study | 0 | ||||||||||||||||||||||||
| Overall Study | 1 | ||||||||||||||||||||||||
| Overall Study | 8 | ||||||||||||||||||||||||
Response: Yes or No (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||
| No | Yes | |||||||||
| Overall Study | 9 | |||||||||
| Overall Study | 0 | |||||||||
Nominal scale values: Inactive; Low; Moderate; High (NCT01316770)
Timeframe: Baseline (Study Day 0) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72024067 | Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | ||||||||||||||||
| Moderate | Inactive | Low | High | |||||||||||||||||
| Overall Study | 2 | |||||||||||||||||||
| Overall Study | 7 | |||||||||||||||||||
| Overall Study | 3 | |||||||||||||||||||
| Overall Study | 6 | |||||||||||||||||||
| Overall Study | 0 | |||||||||||||||||||
| Overall Study | 4 | |||||||||||||||||||
| Overall Study | 5 | |||||||||||||||||||
Possible response on nominal scale: Inactive; Low; Moderate; High SDAI. (NCT01316770)
Timeframe: Baseline (Study Day 0) to Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Day 1472024067 | Study Day 2872024067 | Study Day 4272024067 | Study Day 5672024067 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Baseline Low to Study Day High | Baseline Moderate to Study Day Inactive | Baseline Moderate to Study Day Low | Baseline Moderate to Study Day Moderate | Baseline Moderate to Study Day High | Baseline High to Study Day Inactive | Baseline High to Study Day Low | Baseline High to Study Day Moderate | Baseline High to Study Day High | Baseline Inactive to Study Day Inactive | Baseline Inactive to Study Day Low | Baseline Inactive to Study Day Moderate | Baseline Inactive to Study Day High | Baseline Low to Study Day Inactive | Baseline Low to Study Day Low | Baseline Low to Study Day Moderate | |||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Overall Study | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical evaluations of MRI Scans. Possible evaluations include: i) Normal; ii) Abnormal, not clinically significant; iii) Abnormal, clinically significant. (NCT01316770)
Timeframe: Stage II Screening (within 6 wks before Baseline (Study Day 0)) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage II Screening Visit72024065 | Stage II Screening Visit72024066 | Study Day 5672024066 | Study Day 5672024065 | |||||||||
| MRI Normal | MRI Abnormal, not clinically signficant | MRI Abnormal, clinically signficant | ||||||||||
| Dexamethasone Irrigation of Parotid Gland | 5 | |||||||||||
| Placebo Irrigation of Parotid Gland | 5 | |||||||||||
| Dexamethasone Irrigation of Parotid Gland | 4 | |||||||||||
| Placebo Irrigation of Parotid Gland | 4 | |||||||||||
| Dexamethasone Irrigation of Parotid Gland | 0 | |||||||||||
| Placebo Irrigation of Parotid Gland | 6 | |||||||||||
| Dexamethasone Irrigation of Parotid Gland | 3 | |||||||||||
| Placebo Irrigation of Parotid Gland | 3 | |||||||||||
| Dexamethasone Irrigation of Parotid Gland | 1 | |||||||||||
| Placebo Irrigation of Parotid Gland | 0 | |||||||||||
Medical evaluations of Technetium Scans. Possible evaluations include: i) Normal; and ii) Abnormal. (NCT01316770)
Timeframe: Stage II Screening (within 6 wks before Baseline (Study Day 0)) through Study Day 56
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stage II Screening Visit72024066 | Stage II Screening Visit72024065 | Study Day 5672024066 | Study Day 5672024065 | |||||
| Normal | Abnormal | |||||||
| Dexamethasone Irrigation of Parotid Gland | 4 | |||||||
| Placebo Irrigation of Parotid Gland | 5 | |||||||
| Dexamethasone Irrigation of Parotid Gland | 5 | |||||||
| Placebo Irrigation of Parotid Gland | 4 | |||||||
18 reviews available for prednisolone and Sjogren's Syndrome
| Article | Year |
|---|---|
Co-Existence of Sarcoidosis and Sjögren's Syndrome with Hypercalcemia and Renal Involvement: A Case Report and Literature Review.
Topics: Aged; Anti-Inflammatory Agents; Comorbidity; Humans; Hypercalcemia; Male; Prednisolone; Renal Insuff | 2021 |
Psychiatric manifestations of primary Sjögren's syndrome: a case report and literature review.
Topics: Antipsychotic Agents; Antirheumatic Agents; Benzodiazepines; Female; Glucocorticoids; Hallucinations | 2014 |
Severe Sensory Neuronopathy in Primary Sjögren Syndrome Resulting in Charcot Arthropathy.
Topics: Aged; Ankle Fractures; Arthropathy, Neurogenic; Electromyography; Female; Follow-Up Studies; Fractur | 2016 |
Annular erythema associated with Sjögren's syndrome: review of the literature on the management and clinical analysis of skin lesions.
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents; Antimalarials; Asian People | 2010 |
Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CD5 An | 2012 |
[A case of Sjögren's syndrome with subacute transverse myelitis as the initial manifestation].
Topics: Anti-Inflammatory Agents; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myelitis, Transvers | 2002 |
[Dementia due to cerebral vasculitis].
Topics: Anti-Inflammatory Agents; Bacterial Infections; Cyclophosphamide; Dementia; Drug Therapy, Combinatio | 2004 |
[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy].
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, C | 2004 |
[Diagnosis and therapy for Sjogren syndrome].
Topics: Antibodies, Antinuclear; Antibodies, Monoclonal; Autoimmunity; Biomarkers; Diagnosis, Differential; | 2007 |
Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia.
Topics: Biopsy; Cryptogenic Organizing Pneumonia; Female; Glucocorticoids; Humans; Middle Aged; Muscle, Skel | 1996 |
[Coping with pathological changes in digestive system and kidney in collagen diseases--special reference to Sjogren's syndrome and interstitial nephritis].
Topics: Anti-Inflammatory Agents; Calcium; Female; Humans; Kidney; Middle Aged; Nephritis, Interstitial; Pre | 1996 |
A case of Sjögren's syndrome associated with Sweet's syndrome.
Topics: Acute Kidney Injury; Biopsy, Needle; Glucocorticoids; Humans; Kidney; Male; Middle Aged; Nephritis, | 1997 |
[A case of primary Sjögren's syndrome accompanied by transverse myelitis].
Topics: Anti-Inflammatory Agents; Female; Humans; Middle Aged; Myelitis, Transverse; Peripheral Nervous Syst | 1998 |
Fetal treatment of congenital heart block ascribed to anti-SSA antibody: case reports with observation of cardiohemodynamics and review of the literature.
Topics: Adult; Antibodies, Antinuclear; Autoantigens; Dexamethasone; Echocardiography; Female; Fetal Disease | 1999 |
[Marked improvement by corticosteroid therapy for tumor-forming pancreatitis with Sjögren's syndrome, a case study].
Topics: Anti-Inflammatory Agents; Humans; Male; Middle Aged; Pancreatitis; Prednisolone; Sjogren's Syndrome | 2000 |
[A case of Sjögren's syndrome with pleural effusion].
Topics: Female; Humans; Middle Aged; Pleural Effusion; Prednisolone; Sjogren's Syndrome; Treatment Outcome | 2000 |
[Sjögren's syndrome].
Topics: Antibodies, Antinuclear; Autoimmunity; Cytokines; Diagnosis, Differential; Humans; Prednisolone; Pro | 2000 |
Two cases of Sjögren's syndrome with multiple bullae.
Topics: Aged; Airway Obstruction; Autoimmune Diseases; Blister; Female; Forced Expiratory Volume; Humans; Hy | 2002 |
7 trials available for prednisolone and Sjogren's Syndrome
| Article | Year |
|---|---|
Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Connective Tissue Diseases; Female; Glucocorticoids; Humans | 2021 |
[The clinical observation of different therapeutic strategies in combined primary biliary cirrhosis and Sjögren syndrome].
Topics: Adult; Azathioprine; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Prednisolone; Sjog | 2012 |
Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren's syndrome.
Topics: Adult; Aged; Female; Glucocorticoids; Humans; Middle Aged; Parotid Gland; Prednisolone; Salivation; | 1998 |
Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome.
Topics: Adult; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Pilot Projects; Prednisolone | 1999 |
Disproportion of helper T cell subsets in peripheral blood of patients with primary Sjögren's syndrome.
Topics: Female; Humans; Interferon-gamma; Interleukin-4; Leukocytes, Mononuclear; Prednisolone; Sjogren's Sy | 2000 |
[Comparative evaluation of the treatment of Sjögren's syndrome with anti-rheumatic preparations].
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Chlorambucil; Chloroquine; Clinical Trials as Topic; Dr | 1988 |
[Reports on long-term treatments with sintisone (prednisolon-stearoylglycolate)].
Topics: Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Clinical Trials as Topic; Drug Evaluation; Eosinophi | 1974 |
184 other studies available for prednisolone and Sjogren's Syndrome
| Article | Year |
|---|---|
An Elderly Male with Primary Sjögren's Syndrome Presenting Pleuritis as the Initial Manifestation.
Topics: Aged; Anti-Inflammatory Agents; Diagnosis, Differential; Humans; Male; Pleurisy; Prednisolone; Sjogr | 2021 |
Sjögren's Syndrome Presenting with Temporary Hemiplegia Mimicking Transient Ischemic Attack.
Topics: Cyclophosphamide; Female; Hemiplegia; Humans; Ischemic Attack, Transient; Middle Aged; Prednisolone; | 2022 |
Recurrent aseptic meningitis: A rare clinical presentation of Sjogren's syndrome.
Topics: Antibodies, Antinuclear; Antirheumatic Agents; Fatigue; Female; Glucocorticoids; Humans; Hydroxychlo | 2019 |
Neuro-Sweet disease in a Japanese woman with Sjögren's syndrome.
Topics: Adrenal Cortex Hormones; Adult; Behcet Syndrome; Diagnosis, Differential; Female; Humans; Meningitis | 2019 |
Inclusion-body myositis and primary Sjögren syndrome: mechanisms for shared etiologies.
Topics: 5'-Nucleotidase; Adult; Autoantibodies; Azathioprine; CD8-Positive T-Lymphocytes; Female; Haplotypes | 2020 |
Primary Sjogren's syndrome manifesting with distal renal tubular acidosis and severe metabolic bone disease.
Topics: Absorptiometry, Photon; Acidosis, Renal Tubular; Adolescent; Antirheumatic Agents; Arthralgia; Bone | 2020 |
Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer.
Topics: Antineoplastic Agents; Female; Humans; Nivolumab; Pilocarpine; Prednisolone; Salivary Glands; Sjogre | 2020 |
Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
Topics: Adolescent; Child; Cohort Studies; Europe; Female; Glucocorticoids; Humans; Immunosuppressive Agents | 2020 |
Unusual course of generalized lymph node primary plasmacytoma in a patient with Sjögren's syndrome: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 2017 |
[Severe Interstitial Lung Disease and Manic Symptoms Secondary to Corticosteroids in a Patient with Systemic Lupus Erythematosus and Secondary Sjögren's Syndrome].
Topics: Bipolar Disorder; Female; Glucocorticoids; Humans; Lung Diseases, Interstitial; Lupus Erythematosus, | 2017 |
Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
Topics: Adaptor Proteins, Signal Transducing; Adult; Autoimmune Diseases; Biomarkers; Bone Density; Bone Den | 2018 |
Primary Sjögren's syndrome with Waldenström's macroglobulinemia presenting as unilateral bloody pleural effusion.
Topics: Administration, Oral; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Middle Aged; Pleu | 2017 |
Unresponsiveness to oxytocin due to an extremely thin uterine wall in a pregnant woman with systemic lupus erythematosus and Sjögren's syndrome.
Topics: Adult; Cesarean Section; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Hyster | 2018 |
Aire-deficient mice provide a model of corneal and lacrimal gland neuropathy in Sjögren's syndrome.
Topics: AIRE Protein; Animals; CD4-Positive T-Lymphocytes; Cell Proliferation; Cornea; Disease Models, Anima | 2017 |
Hypertrophic Pachymeningitis in Sjögren's Syndrome.
Topics: Adult; Anti-Inflammatory Agents; Female; Humans; Hypertrophy; Meningitis; Prednisolone; Sjogren's Sy | 2018 |
Reactivity to anti-RNA polymerase III antibody and nailfold capillary changes in patient with generalized morphea combined with multiple autoimmune disorders.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Antinuclear; Capillaries; Female; Hepatitis, Autoimmune; | 2018 |
Emergence of Smoldering ANCA-associated Glomerulonephritis during the Clinical Course of Mixed Connective Tissue Disease and Sjögren's Syndrome.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Female; Glomerulonephritis; Humans; Mixed Connective T | 2018 |
Sjögren's syndrome manifesting as clinicopathological features of TAFRO syndrome: A case report.
Topics: Adult; Castleman Disease; Diagnosis, Differential; Female; Glucocorticoids; Humans; Prednisolone; Sj | 2017 |
A Case of Sjögren's Syndrome Complicated with Interstitial Nephritis and Delayed Onset Autoimmune Hepatitis.
Topics: Acidosis, Renal Tubular; Administration, Oral; Female; Hepatitis, Autoimmune; Humans; Hypokalemia; K | 2018 |
Sjögren's and plasma cell variant Castleman disease: a case report.
Topics: Adult; Anemia, Hemolytic; Castleman Disease; Chlorambucil; Diagnosis, Differential; Drug Therapy, Co | 2018 |
Renal involvement in primary Sjogren's syndrome: a prospective cohort study.
Topics: Acidosis, Renal Tubular; Adult; Asymptomatic Diseases; Biopsy; Case-Control Studies; Female; Glomeru | 2018 |
Autoimmune autonomic ganglionopathy associated with Sjögren's syndrome presenting with recurrent abdominal distension.
Topics: Aged; Autoantibodies; Autoimmune Diseases of the Nervous System; Diagnosis, Differential; Female; Ga | 2018 |
Sjogren's syndrome presenting with hypokalemic periodic paralysis.
Topics: Acidosis, Renal Tubular; Administration, Intravenous; Adult; Antibodies, Antinuclear; Female; Glucoc | 2012 |
[Interdisciplinary approach in a patient with IgG4-associated Mikulicz's disease].
Topics: Anti-Inflammatory Agents; Diagnosis, Differential; Humans; Immunoglobulin G; Male; Middle Aged; Miku | 2013 |
Co-development of autoimmune hepatitis and Sjögren's syndrome triggered by the administration of herbal medicines.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Azathioprine; Bilirubin; Female; Hepatitis, Autoi | 2013 |
SLE and dental erosion: a lethal cocktail.
Topics: Adolescent; Anti-Inflammatory Agents; Antirheumatic Agents; Chloroquine; Female; Fever; Fruit; Human | 2014 |
Autoimmune myelofibrosis accompanied by Sjögren's syndrome in a 47, XXX/46, XX mosaic woman.
Topics: Adult; Chromosomes, Human, X; Female; Follow-Up Studies; Genetic Testing; Glucocorticoids; Humans; P | 2014 |
Interstitial cystitis associated with primary Sjögren's syndrome successfully treated with a combination of tacrolimus and corticosteroid: A case report and literature review.
Topics: Adrenal Cortex Hormones; Aged; Cystitis, Interstitial; Drug Therapy, Combination; Female; Humans; Pr | 2016 |
Autoimmune haemolytic anaemia as an initial presentation of primary Sjögren syndrome.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Antirheumatic Agents; Blood Volume; | 2014 |
Organizing pneumonia with atypical computed tomography findings in Sjögren's syndrome.
Topics: Cryptogenic Organizing Pneumonia; Female; Follow-Up Studies; Humans; Middle Aged; Prednisolone; Risk | 2015 |
Corticoid therapy for overlapping syndromes in an HIV-positive patient.
Topics: Adult; Anti-Retroviral Agents; Hepatitis, Autoimmune; HIV Infections; Humans; Male; Polymyositis; Pr | 2015 |
Development of mixed connective tissue disease and Sjögren's syndrome in a patient with trisomy X.
Topics: Adolescent; Antibodies, Antinuclear; Antibodies, Monoclonal, Humanized; Chromosomes, Human, X; Femal | 2015 |
Complication of chronic eosinophilic pneumonia in an elderly patient with Sjögren syndrome.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged, 80 and over; Chronic Disease; Humans; Male; Pre | 2015 |
Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Cryptogenic Organizing Pneumonia; Drug Ther | 2015 |
Sjögren's syndrome associated with protein losing gastroenteropathy manifested by intestinal lymphangiectasia successfully treated with prednisolone and hydroxychloroquine.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lymphangi | 2015 |
Prevention of recurrent congenital heart block in a SSA/SSB positive mother using high dose maternal IVIG from 16-week gestation.
Topics: Adult; Antibodies, Antinuclear; Dexamethasone; Female; Glucocorticoids; Heart Block; Humans; Immunog | 2015 |
Salivary gland ultrasonography as a primary imaging tool for predicting efficacy of xerostomia treatment in patients with Sjögren's syndrome.
Topics: Administration, Oral; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucocortic | 2016 |
Persistent hiccups followed by acute respiratory failure.
Topics: Anti-Inflammatory Agents; Deglutition Disorders; Female; Hiccup; Humans; Prednisolone; Respiratory D | 2016 |
Multiple Mesenteric Panniculitis as a Complication of Sjögren's Syndrome Leading to Ileus.
Topics: Aged; Female; Humans; Ileus; Intestinal Diseases; Mesentery; Panniculitis, Peritoneal; Prednisolone; | 2016 |
Steroid-resistant protein-losing gastroenteropathy complicated with Sjögren's syndrome successfully treated with mizoribine.
Topics: Female; Glucocorticoids; Humans; Immunosuppressive Agents; Middle Aged; Prednisolone; Protein-Losing | 2018 |
Anti-signal recognition particle antibody-positive polymyositis in a patient with Sjögren's syndrome showing various types of annular erythema: Positive correlation between the activities of annular erythema and myositis.
Topics: Arthritis, Rheumatoid; Autoantibodies; Erythema; Humans; Male; Middle Aged; Polymyositis; Prednisolo | 2016 |
Severe Thrombocytopenia as Initial Signs of Primary Sjögren Syndrome in a 9-Year-Old Female.
Topics: Child; Female; Humans; Prednisolone; Sjogren's Syndrome; Thrombocytopenia | 2016 |
Anterior horn syndrome: A rare manifestation of primary Sjögren's syndrome.
Topics: Electromyography; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Methylprednisolone; | 2016 |
Hypokalemic Paralysis in Sjogren's Syndrome Secondary to Renal Tubular Acidosis.
Topics: Acetazolamide; Acidosis, Renal Tubular; Adult; Female; Humans; Hypokalemia; Immunosuppressive Agents | 2016 |
Sensorineural hearing loss as the first manifestation of Sjögren's syndrome.
Topics: Aged; Audiometry; Female; Glucocorticoids; Hearing Loss, Sensorineural; Humans; Prednisolone; Sjogre | 2017 |
[Case of systemic lupus erythematosus occurring after induced abortion and drug eruption].
Topics: Abortion, Induced; Adult; Anticonvulsants; Diagnosis, Differential; Drug Eruptions; Female; Humans; | 2008 |
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Diagnosis, Differential; Female; Glucocorticoids | 2009 |
Bilateral basal ganglia lesions of primary Sjogren syndrome presenting with generalized chorea.
Topics: Aged; Anti-Dyskinesia Agents; Basal Ganglia Diseases; Chorea; Functional Laterality; Glucocorticoids | 2009 |
[Cyclic thrombocytopenia complicated with Sjögren syndrome and the mechanism of periodic platelet count fluctuation].
Topics: Aged; Female; Humans; Immunoglobulin G; Periodicity; Platelet Count; Prednisolone; Purpura, Thromboc | 2008 |
An autopsy case of Sjögren's syndrome with acute encephalomyelopathy.
Topics: Adult; Autopsy; Brain Stem; Central Nervous System Diseases; Female; Humans; Intestinal Pseudo-Obstr | 2008 |
Multinodular pulmonary amyloidosis in primary Sjögren's syndrome.
Topics: Amyloidosis; Biopsy; Female; Glucocorticoids; Humans; Lung Diseases, Interstitial; Middle Aged; Pred | 2008 |
Autoimmune autonomic ganglionopathy with Sjögren's syndrome: significance of ganglionic acetylcholine receptor antibody and therapeutic approach.
Topics: Aged; Antibodies, Antinuclear; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous Syst | 2009 |
Pulmonary manifestations of Sjögren's syndrome.
Topics: Adult; Antirheumatic Agents; Cyclophosphamide; Female; Glucocorticoids; Humans; Lung; Lung Diseases, | 2009 |
[Steroid-induced spinal epidural lipomatosis in pediatric patients].
Topics: Adolescent; Anti-Inflammatory Agents; Arthritis, Juvenile; Child; Drug Therapy, Combination; Epidura | 2010 |
[Neuromyelitis optica in a patient with Sjögren syndrome with distal renal tubular acidosis: case report].
Topics: Acidosis, Renal Tubular; Adult; Aquaporin 4; Autoantibodies; Biomarkers; Female; Humans; Methylpredn | 2010 |
Primary Sjögren syndrome that developed after IgA nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Infla | 2010 |
Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjögren's syndrome.
Topics: Adrenal Cortex Hormones; Agglutination; Agglutination Tests; Anemia, Hemolytic, Autoimmune; Autoanti | 2010 |
Primary Sjögren's syndrome with myalgia mimicking dermatomyositis.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Dermatomyositis; E | 2010 |
Rituximab and lupus interstitial lung disease: friend or foe?
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Drug Therapy, Combination; Dysp | 2011 |
A case of primary Sjögren's syndrome presenting primarily with central nervous system vasculitic involvement.
Topics: Adult; Angiography, Digital Subtraction; Azathioprine; Brain; Central Nervous System Diseases; Diagn | 2012 |
Long-term remission of pulmonary veno-occlusive disease associated with primary Sjögren's syndrome following immunosuppressive therapy.
Topics: Azathioprine; Female; Heart Failure; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Pred | 2011 |
Sjogren's thrombocytopenia.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antihypertensive Agents; Autoimmune Diseases; Female; Humans; | 2011 |
Distal renal tubular acidosis associated with Sjögren's syndrome.
Topics: Acidosis, Renal Tubular; Biopsy; Female; Humans; Immunosuppressive Agents; Middle Aged; Nephrocalcin | 2012 |
Extremely high salivary β(2) -microglobulin and Na(+) levels in a Sjögren syndrome patient.
Topics: beta 2-Microglobulin; Female; Glucocorticoids; Humans; Middle Aged; Prednisolone; Saliva; Salivary G | 2012 |
Recurrent parotitis as a first manifestation in a child with primary Sjogren's syndrome.
Topics: Antirheumatic Agents; Child; Diagnosis, Differential; Glucocorticoids; Humans; Male; Methotrexate; P | 2011 |
Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome.
Topics: Acidosis, Renal Tubular; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid | 2013 |
Hypokalemic paralysis in a girl with dental and renal calculi. Distal renal tubular acidosis (RTA).
Topics: Acidosis, Renal Tubular; Adolescent; Child; Child, Preschool; Dental Calculus; Dental Restoration, P | 2013 |
[Case of Takayasu's arteritis (type V) together with Sjögrens's syndrome and Basedow's disease].
Topics: Antithyroid Agents; Female; Graves Disease; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome; T | 2002 |
Autoimmune enteropathy in an adult with autoimmune multisystemic involvement.
Topics: Autoantibodies; Autoimmune Diseases; Autoimmunity; CD4-Positive T-Lymphocytes; CD8-Positive T-Lympho | 2002 |
Anterior uveitis and Sjögren's syndrome in a patient with primary biliary cirrhosis.
Topics: Administration, Topical; Drug Therapy, Combination; Female; Humans; Liver Cirrhosis, Biliary; Middle | 2002 |
[Autoimmune meningitis simulating bacterial meningitis].
Topics: Adult; Anti-Inflammatory Agents; Antibiotics, Antitubercular; Autoimmune Diseases; Female; Fever; Hu | 2002 |
Atypical autoimmune blistering dermatosis associated with Sjögren's syndrome.
Topics: Autoantibodies; Autoimmune Diseases; Collagen Type VII; Female; Glucocorticoids; Humans; Middle Aged | 2002 |
Cogan's syndrome presenting as Sjögren's syndrome followed by acute aortic regurgitation.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Aortic Valve Insufficiency; Au | 2003 |
[A case of Sjögren syndrome accompanied by interstitial cystitis and interstitial pneumonia improved by suplatast tosilate and prednisolone].
Topics: Aged; Arylsulfonates; Cystitis, Interstitial; Drug Therapy, Combination; Female; Humans; Lung Diseas | 2003 |
[Two cases of interstitial nephritis with primary Sjögren's syndrome successfully treated by steroid therapy].
Topics: Anti-Inflammatory Agents; Female; Humans; Kidney; Middle Aged; Nephritis, Interstitial; Prednisolone | 2003 |
Sjogren's syndrome presenting as remitting seronegative symmetric synovitis with pitting edema (RS3PE).
Topics: Adult; Antibodies, Antinuclear; Arthritis; Biopsy; Blood Sedimentation; Diagnosis, Differential; Ede | 2003 |
Autoimmune aspects of pulmonary hypertension in collagen vascular diseases.
Topics: Connective Tissue Diseases; Glucocorticoids; Humans; Hypertension, Pulmonary; Prednisolone; Sjogren' | 2003 |
Severe pulmonary hypertension associated with primary Sjögren's syndrome.
Topics: Adult; Antigen-Antibody Complex; Complement C1q; Female; Glucocorticoids; Humans; Hypertension, Pulm | 2003 |
[Secondary bronchiolitis obliterans organizing pneumonia with primary Sjögren's syndrome, resulting in acute respiratory distress syndrome: a case report].
Topics: Aged; Cryptogenic Organizing Pneumonia; Fatal Outcome; Female; Humans; Prednisolone; Pulse Therapy, | 2004 |
Severe interstitial cystitis associated with Sjögren's syndrome.
Topics: Cyclosporine; Cystitis, Interstitial; Female; Glucocorticoids; Humans; Hydronephrosis; Immunosuppres | 2004 |
A 70-year-old man with weight loss, dry mouth and renal insufficiency.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Biopsy; Humans; Kidney; Magnetic Resonance Ima | 2004 |
Cricoarytenoid arthritis in Sjögren's syndrome.
Topics: Anti-Inflammatory Agents; Arytenoid Cartilage; Cricoid Cartilage; Female; Humans; Laryngeal Diseases | 2005 |
Anti-ribosomal-P antibodies in a Sjögren syndrome patient associated with lupus erythematosus.
Topics: Adult; Autoantibodies; Biomarkers; Biopsy, Needle; Female; Fluorescent Antibody Technique, Indirect; | 2004 |
Prurigo pigmentosa in a patient with primary biliary cirrhosis and Sjögren syndrome.
Topics: Administration, Oral; Adult; Biopsy, Needle; Female; Follow-Up Studies; Humans; Hyperpigmentation; I | 2004 |
Coexisting ankylosing spondylitis and Sjogren's syndrome: a case report.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non | 2005 |
[Case of primary Sjögren's syndrome with hypereosinophilia and elevation of serum IgE: measurements of serum IL-4, IL-5 and the IgG subclass].
Topics: Eosinophilia; Humans; Hypergammaglobulinemia; Immunoglobulin E; Immunoglobulin G; Interleukin-4; Int | 2005 |
[Three patients with nephrotic syndrome due to membranous nephropathy complicated by Sjögren's syndrome].
Topics: Adult; Anti-Inflammatory Agents; Female; Glomerulonephritis, Membranous; Humans; Liver Cirrhosis, Bi | 2005 |
Middle lobe syndrome as the pulmonary manifestation of primary Sjögren's syndrome.
Topics: Female; Glucocorticoids; Humans; Lung; Middle Aged; Middle Lobe Syndrome; Prednisolone; Radiography; | 2006 |
[Case of subcutaneous and mesenteric acute panniculitis with Sjögren's syndrome].
Topics: Acute Disease; Adult; Female; Humans; Mesentery; Panniculitis; Prednisolone; Sjogren's Syndrome; Sub | 2002 |
Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy.
Topics: Administration, Oral; Aged; Autoimmune Diseases; Biliary Tract; Cholangiopancreatography, Endoscopic | 2006 |
[A case of systemic sclerosis and Sjogren's syndrome with cardiac tamponade due to steroid-responsive pericarditis].
Topics: Aged; Cardiac Tamponade; Female; Humans; Pericarditis; Prednisolone; Scleroderma, Diffuse; Sjogren's | 2006 |
Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Female; Glucocorticoids; Humans; In | 2007 |
Recurrent aseptic meningitis: a new CSF complication of Sjogren's syndrome.
Topics: Adult; Autoantibodies; Autoimmune Diseases of the Nervous System; Biomarkers; Chronic Disease; Diagn | 2007 |
Cryofibrinogenemia associated with Sjögren's syndrome: a case of successful treatment with high-dose corticosteroid.
Topics: Adult; Cryoglobulinemia; Cryoglobulins; Dose-Response Relationship, Drug; Drug Administration Schedu | 2007 |
Successful treatment of a patient with primary Sjögren's syndrome complicated with pericarditis during pregnancy.
Topics: Adult; Female; Glucocorticoids; Humans; Pericarditis; Prednisolone; Pregnancy; Pregnancy Complicatio | 2007 |
Effect of steroid administration and plasmapheresis to prevent fetal congenital heart block in patients with systemic lupus erythematosus and/or Sjögren's syndrome.
Topics: Antibodies, Antinuclear; Female; Glucocorticoids; Heart Block; Humans; Infant, Newborn; Lupus Erythe | 2007 |
Severe pulmonary hypertension in pediatric primary Sjögren syndrome: a case report.
Topics: Antirheumatic Agents; Child; Cyclophosphamide; Female; Humans; Hypertension, Pulmonary; Prednisolone | 2007 |
Bilateral periocular psoriasis: an initial manifestation of acute generalized pustular psoriasis with coexistent Sjögren's syndrome.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Adult; Betamethasone; Drug Therapy, Co | 2007 |
A case of proteinase 3-antineutrophil cytoplasmic antibody-positive Sjögren's syndrome complicated with interstitial nephritis.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Female; Humans; Myeloblastin; Nephritis, Interstitial; | 2007 |
[Successful treatment with prednisolone for autoimmune myelofibrosis accompanied with Sjögren syndrome].
Topics: Aged; Autoimmune Diseases; Female; Humans; Prednisolone; Primary Myelofibrosis; Sjogren's Syndrome | 2007 |
[Is rituximab a promising treatment for Sjögren's syndrome?].
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; A | 2008 |
Glomeruloid hemangioma.
Topics: Biomarkers, Tumor; Castleman Disease; Female; Hemangioma; Humans; Lymph Nodes; Middle Aged; Parotid | 2008 |
Systemic lupus erythematosus with lichen planus-like eruptions associated with pericarditis.
Topics: Adult; Diagnosis, Differential; Female; Glucocorticoids; Humans; Lichen Planus; Lupus Erythematosus, | 2008 |
Dramatic regression of mesenteric abnormalities demonstrated on angiography following prednisolone and cyclophosphamide combination therapy in a patient with polyarteritis nodosa associated with Sjögren's syndrome.
Topics: Angiography; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Mesenteric Artery, Superio | 2008 |
A case of mixed connective tissue disease complicated with hypertrophic obstructive cardiomyopathy.
Topics: Anti-Inflammatory Agents; Cardiomyopathy, Hypertrophic; Female; HLA-DR4 Antigen; Humans; Lung Diseas | 2008 |
Sjögren's syndrome presenting as a severe sensory neuropathy including involvement of the trigeminal nerve.
Topics: Adult; Cranial Nerve Diseases; Diagnosis, Differential; Female; Humans; Peripheral Nervous System Di | 1984 |
[Multiple colonic ulcers in a patient with Sjögren's syndrome].
Topics: Adult; Anti-Inflammatory Agents; Colonic Diseases; Female; Humans; Prednisolone; Sjogren's Syndrome; | 1995 |
[The therapy of Sjögren's syndrome].
Topics: Bronchitis; Chronic Disease; Cyclophosphamide; Female; Humans; Methotrexate; Middle Aged; Prednisolo | 1995 |
Acquired Brown's syndrome and primary Sjogren's syndrome.
Topics: Adult; Chloroquine; Diplopia; Female; Humans; Ophthalmoplegia; Prednisolone; Sjogren's Syndrome | 1995 |
Corticosteroid-responsive parkinsonism associated with primary Sjögren's syndrome.
Topics: Aged; Biopsy; Brain; Female; Humans; Magnetic Resonance Imaging; Neurologic Examination; Parkinson D | 1994 |
Neonatal lupus erythematosus: dissolution of atrioventricular block after administration of corticosteroid to the pregnant mother.
Topics: Female; Fetal Diseases; Heart Block; Humans; Infant; Lupus Erythematosus, Cutaneous; Prednisolone; P | 1994 |
[Sjögren's disease].
Topics: Adult; Antibodies, Antinuclear; Female; Humans; Middle Aged; Prednisolone; Rheumatoid Factor; Sialog | 1994 |
Aseptic meningoencephalitis in primary Sjögren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy.
Topics: Adolescent; Brain; Cyclophosphamide; Female; Humans; Meningoencephalitis; Plasmapheresis; Prednisolo | 1993 |
Primary Sjögren's syndrome with subcortical dementia.
Topics: Brain; Creatine Kinase; Dementia; Electroencephalography; Humans; Magnetic Resonance Imaging; Male; | 1993 |
Astasia-abasia revealing a primary Sjögren's syndrome.
Topics: Brain; Conversion Disorder; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Immunoglobulins; M | 1993 |
Central nervous system disease in a child with primary Sjögren syndrome.
Topics: Brain; Child; Diagnosis, Differential; Encephalomyelitis; Female; Hemiplegia; Humans; Immunoglobulin | 1995 |
[Primary Sjögren's syndrome accompanied by pleural effusion].
Topics: Adult; Female; Humans; Pleural Effusion; Prednisolone; Sjogren's Syndrome | 1995 |
[A case of Sjögren's syndrome with lymphocytic interstitial pneumonia].
Topics: Aged; Anti-Inflammatory Agents; Autoantibodies; CD3 Complex; CD4-CD8 Ratio; Female; Humans; Lung Dis | 1996 |
Primary Sjögren's syndrome, ulcerative colitis and selective IgA deficiency.
Topics: Adolescent; Azathioprine; Colitis, Ulcerative; Gastrointestinal Agents; Humans; IgA Deficiency; Immu | 1996 |
[Sjögren's syndrome complicated by thymoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cycloph | 1996 |
Hypergammaglobulinemic purpura associated with Sjögren's syndrome and chronic C type hepatitis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Antinuclear; Cryoglobulins; Female; H | 1997 |
Mixed-cryoglobulinemia associated with cutaneous vasculitis and pulmonary symptoms.
Topics: Cryoglobulinemia; Dyspnea; Glucocorticoids; Humans; Hypoxia; Male; Middle Aged; Prednisolone; Pulmon | 1997 |
[A case of Sjögren's syndrome with a high titer of anticardiolipin antibody that developed as parkinsonism].
Topics: Antibodies, Anticardiolipin; Azathioprine; Glucocorticoids; Humans; Immunosuppressive Agents; Male; | 1997 |
[Interstitial pneumonia with Sjögren's syndrome: successful treatment with steroids and an immunosuppressant].
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Drug Therapy, Combination; Dyspnea; Female; Humans; I | 1997 |
[Case of remitting seronegative symmetrical synovitis with pitting edema complicated with Sjogren syndrome].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Edema; Fem | 1997 |
Multiple pancreatic masses associated with autoimmunity.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antibodies, Antinuclear; Autoimmune Diseases; Biopsy | 1998 |
Optic neuropathy in a child with primary Sjögren's syndrome.
Topics: Adolescent; Biopsy, Needle; Child; Diagnosis, Differential; Female; Follow-Up Studies; Glucocorticoi | 1998 |
Polymyalgia rheumatica in a patient with acute tubulointerstitial nephritis due to Sjögren's syndrome.
Topics: Aged; Female; Glucocorticoids; Humans; Methylprednisolone; Nephritis, Interstitial; Polymyalgia Rheu | 1998 |
[Primary Sjögren's syndrome with pulmonary hypertension].
Topics: Anemia, Hemolytic; Anti-Inflammatory Agents; Cyclophosphamide; Female; Humans; Hypergammaglobulinemi | 1998 |
[A case of Sjögren's syndrome associated with advanced hemolytic anemia caused by worsening autoimmune cholangiopathy].
Topics: Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Autoimmune Diseases; Bile Duct Diseases; Fe | 1998 |
[Peripheral neuropathy and dysautonomia in a patient with primary Sjögren's syndrome].
Topics: Autonomic Nervous System Diseases; Female; Glucocorticoids; Humans; Hypohidrosis; Hypotension, Ortho | 1998 |
Subclinical Sjögren's syndrome: a significant 67gallium accumulation in the orbits and parotid glands.
Topics: Anti-Inflammatory Agents; Child; Female; Gallium Radioisotopes; Humans; Orbit; Parotid Gland; Predni | 1998 |
[Primary Sjögren's syndrome and glomerulonephritis].
Topics: Aged; Aged, 80 and over; Biopsy; Cyclosporine; Drug Therapy, Combination; Female; Glomerulosclerosis | 1998 |
Calcitriol-mediated hypercalcaemia and increased interleukins in a patient with sarcoid myopathy.
Topics: Antirheumatic Agents; Calcitonin; Calcitriol; Chloroquine; Clodronic Acid; Female; Humans; Hypercalc | 1999 |
Sjögren's syndrome complicated with autoimmune hepatitis and antiphospholipid antibody syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Cytokines; Female; Glucocorticoids; Hepatit | 2000 |
[A case of Sjögren's syndrome with retrobulbar optic neuritis and cutaneous vasculitis].
Topics: Female; Humans; Middle Aged; Optic Neuritis; Prednisolone; Pulse Therapy, Drug; Purpura; Sjogren's S | 1999 |
Diminished expression of CD59 on activated CD8+ T cells undergoing apoptosis in systemic lupus erythematosus and Sjögren's syndrome.
Topics: Apoptosis; CD59 Antigens; CD8-Positive T-Lymphocytes; Cells, Cultured; Down-Regulation; Humans; Immu | 2000 |
[A male case of Sjögren's syndrome presenting with generalized lymphadenopathy and swelling of both lacrimal and salivary glands which responded remarkably well to an administration of corticosteroids].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Antinuclear; Humans; Lacrimal Apparatus; Lymphatic Disea | 2000 |
Sjögren's syndrome and multiple amyloidomas.
Topics: Aged; Amyloidosis; Anti-Inflammatory Agents; Humans; Male; Melphalan; Prednisolone; Sjogren's Syndro | 2000 |
A patient with heat insoluble cryoglobulin.
Topics: Aged; Aged, 80 and over; Cryoglobulinemia; Cryoglobulins; Hot Temperature; Humans; Male; Prednisolon | 2000 |
Multicentric reticulohistiocytosis associated with Sjögren's syndrome.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Female; Histiocytosis, Non-Langerhans-Cell; Humans; | 2000 |
Oral prednisolone improved acetylcholine-induced sweating in Sjögren's syndrome-related anhidrosis.
Topics: Acetylcholine; Administration, Oral; Aged; Female; Glucocorticoids; Humans; Hyperhidrosis; Hypohidro | 2000 |
[A case of primary Sjögren's syndrome with interstitial pneumonia showing bronchiolitis obliterans organizing pneumonia pattern and lymphofollicular formation].
Topics: Administration, Oral; Biopsy; Cryptogenic Organizing Pneumonia; Female; Humans; Lung Diseases, Inter | 2000 |
Successful treatment of embryo implantation failure in patients with the Sjögren syndrome with low-dose prednisolone.
Topics: Adult; Embryo Implantation; Embryo Transfer; Female; Fertilization in Vitro; Glucocorticoids; Humans | 2001 |
[Sjögren's syndrome with multiple bullae and pulmonary nodular amyloidosis].
Topics: Amyloidosis; Antiphospholipid Syndrome; Blister; Bronchiolitis; Diagnosis, Differential; Female; Hum | 2000 |
[A case of Sjögren's syndrome with dermatomyositis who died of rapidly progressive interstitial pneumonia].
Topics: Cyclophosphamide; Cyclosporine; Dermatomyositis; Disease Progression; Fatal Outcome; Female; Humans; | 2001 |
Autoimmune hepatitis concomitant with hypergammaglobulinemic purpura, immune thrombocytopenia, and Sjögren's syndrome.
Topics: Anti-Inflammatory Agents; Female; Hepatitis, Autoimmune; Humans; Hypergammaglobulinemia; Middle Aged | 2001 |
Motor dominant neuropathy in Sjögren's syndrome: report of two cases.
Topics: Aged; Autoimmune Diseases; Biopsy; Diagnosis, Differential; Female; Guillain-Barre Syndrome; Humans; | 2002 |
Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects.
Topics: Aged; Anti-Inflammatory Agents; Azathioprine; Biopsy; Humans; Immunosuppressive Agents; Infant; Magn | 2002 |
Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients.
Topics: Adult; Arthritis, Rheumatoid; Autoimmune Diseases; Autoimmunity; Female; Gene Expression Regulation; | 2002 |
[Cellular immunity in Sjögren's syndrom (author's transl)].
Topics: Adult; Antibody Formation; Cell Migration Inhibition; Epitopes; Humans; Immunity, Cellular; Lymphocy | 1977 |
Sjogren's syndrome.
Topics: Cortisone; Humans; Prednisolone; Sjogren's Syndrome | 1978 |
Connective tissue disorders in India II. Clinical and immunological studies in Sjogren's syndrome.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Immunoglobulins; India; Middle Aged; Prednisolone; Sj | 1978 |
[Remarkable effects of adrenal cortex hormone in Sjögren's syndrome].
Topics: Female; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome | 1978 |
Successful immunosuppressive therapy in insulin resistant diabetes caused by anti-insulin receptor autoantibodies.
Topics: Autoantibodies; C-Peptide; Cyclophosphamide; Diabetes Complications; Diabetes Mellitus; Female; Gluc | 1977 |
[Application of adrenal cortex steroid hormone therapy and the associated problems].
Topics: Churg-Strauss Syndrome; Humans; Paraproteinemias; Peripheral Nervous System Diseases; POEMS Syndrome | 1992 |
Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus.
Topics: Adult; Antigens, Differentiation, B-Lymphocyte; B-Lymphocytes; Female; Humans; Immunoglobulin A; Imm | 1992 |
[A case of systemic lupus erythematosus associated with Sjögren's syndrome diagnosed by lung localization].
Topics: Adult; Female; Humans; Lung; Lupus Erythematosus, Systemic; Prednisolone; Pulmonary Fibrosis; Radiog | 1992 |
[Progress on diagnosis and therapy of kidney diseases complicated with rheumatoid arthritis and Sjogren's syndrome].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Gold; Humans; Kidney Diseases; Penic | 1992 |
Serum level of interferon-gamma in autoimmune diseases.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antigens, Surface; Arthritis, Rheumatoid; Autoim | 1991 |
Clinical features of patients with mild systemic lupus erythematosus.
Topics: Adolescent; Adult; Autoantigens; Child; Complement C3; Complement C4; Complement Hemolytic Activity | 1991 |
[A case of progressive systemic sclerosis and Sjögren's syndrome complicated by parkinsonism with special reference to the beneficial effect of corticosteroid].
Topics: Aged; Drug Resistance; Female; Humans; Levodopa; Parkinson Disease; Prednisolone; Scleroderma, Syste | 1991 |
Tubulointerstitial disorders in the kidney associated with primary biliary cirrhosis (PBC)
Topics: Female; Humans; Liver Cirrhosis, Biliary; Middle Aged; Nephritis, Interstitial; Prednisolone; Sjogre | 1991 |
Endophthalmitis caused by exogenous nocardial infection in a patient with Sjögren's syndrome.
Topics: Chloramphenicol; Corneal Diseases; Endophthalmitis; Eye Enucleation; Eye Infections, Bacterial; Fema | 1990 |
[Interstitial lung disease in Sjogren's syndrome, MCTD and ankylosing spondylitis].
Topics: Bronchoalveolar Lavage Fluid; Female; Humans; Male; Mixed Connective Tissue Disease; Prednisolone; P | 1990 |
Endobronchial pseudolymphoma associated with Sjögren's syndrome. Report of a case.
Topics: Bronchial Neoplasms; Female; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Prednisolone | 1989 |
Annular erythema: a possible association with primary Sjögren's syndrome.
Topics: Adult; Child; Erythema; Female; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome; Skin | 1989 |
[A case of primary Sjögren syndrome associated with neurogenic bladder].
Topics: Female; Humans; Methylprednisolone; Middle Aged; Prednisolone; Sjogren's Syndrome; Urinary Bladder, | 1989 |
Sjögren syndrome and pseudolymphoma.
Topics: Autoantibodies; Autoimmune Diseases; Cyclophosphamide; Female; Humans; Lymphoma; Middle Aged; Predni | 1988 |
[Four patients with thrombocytopenia associated with Sjögren's syndrome].
Topics: Adult; Aged; Autoantibodies; Bone Marrow Cells; Female; Humans; Immunoglobulin G; Megakaryocytes; Pl | 1988 |
[Comparative evaluation of various methods of treatment of patients with Sjögren's disease and syndrome at the hospital-polyclinic stages].
Topics: Ambulatory Care; Chloroquine; Dose-Response Relationship, Drug; Hospitalization; Humans; Prednisolon | 1988 |
[Clinical study of autoimmune diseases: recent trends--with special reference to progress in immunological tests and the therapeutic methods. Organ-specific autoimmune diseases. 4) Sjogren's syndrome].
Topics: Autoantibodies; Autoantigens; Drugs, Chinese Herbal; Humans; Immunity, Cellular; Prednisolone; Ribon | 1988 |
Successful treatment of aplastic anemia associated with chronic thyroiditis and Sjögren's syndrome.
Topics: Adult; Anemia, Aplastic; Drug Therapy, Combination; Female; Ferrous Compounds; Humans; Prednisolone; | 1986 |
[Malignant lymphoma associated with Sjögren's syndrome: a case report].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1986 |
[Association of autoimmune dementia, Basedow's disease, and Gougerot-Sjögren syndrome].
Topics: Autoimmune Diseases; Dementia; Graves Disease; Humans; Male; Middle Aged; Prednisolone; Sjogren's Sy | 1985 |
Development of chronic lymphocytic leukaemia in a case of Sjögren's syndrome with systemic lupus erythematosus.
Topics: Aged; B-Lymphocytes; Cephalosporins; Female; Gentamicins; Humans; Leukemia, Lymphoid; Lupus Erythema | 1985 |
[Gougerot-Sjögren syndrome with autoimmune thrombopenia treated with cortisone shocks].
Topics: Female; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome; Thrombocytopenia | 1985 |
Histology of the lacrimal gland in keratoconjunctivitis sicca.
Topics: Aged; Arthritis, Rheumatoid; Biopsy; Female; Humans; Inflammation; Keratoconjunctivitis; Lacrimal Ap | 1973 |
[Successful combined immunosuppressive and corticosteroid therapy of Sjögren's disease].
Topics: Adult; Azathioprine; Chloroquine; Female; Humans; Male; Middle Aged; Prednisolone; Sjogren's Syndrom | 1974 |
[The effect of 6-alpha-fluoro-16-alpha-methyl-1-dehydro-corticosterone (fluocortolone) in internal diseases].
Topics: Acute Disease; Adrenal Insufficiency; Adult; Aged; Arthritis, Rheumatoid; Asthma; Bronchitis; Chroni | 1968 |
Lung changes in Sjögren's syndrome.
Topics: Female; Humans; Lung Diseases; Middle Aged; Prednisolone; Pulmonary Fibrosis; Respiratory Function T | 1969 |
Sialopathies in sarcoidosis.
Topics: Adult; Female; Humans; Hypergammaglobulinemia; Isoniazid; Lacrimal Apparatus; Lymph Nodes; Middle Ag | 1970 |
[Use of prednisolone in Sjögren's syndrome].
Topics: Aged; Female; Humans; Middle Aged; Prednisolone; Sjogren's Syndrome | 1967 |
A case of multiple autoimmune disease, lymphoid proliferation and hypogammaglobulinaemia.
Topics: Agammaglobulinemia; Aged; Anemia, Hemolytic, Autoimmune; Antibody Formation; Arthritis, Rheumatoid; | 1968 |